Patent Grant
10159714
The present invention relates to formulations and methods for treating cancer. Aspects of the present invention provide formulations of glucagon-like peptide-1 (GLP-1) receptor agonists for use in mammals for the treatment of cancers.
The contents of the text file named “ITCA-040C01US_ST25”, which was created on Oct. 27, 2014 and is 1,236 bytes in size, are hereby incorporated by reference in their entireties.
Glycolysis is the metabolic pathway that converts glucose into pyruvate. The free energy released in this process is used to form the high-energy compounds ATP and NADH. Increased aerobic glycolysis is seen in a variety of cancer cells, a phenomenon known as the Warburg theory. Under aerobic conditions, some tumor cells produce as much as 60% of their ATP through glycolysis (Nakashima et al., Cancer Res. (1984) 44:5702-5706) as opposed to normal cells which normally generate ATP through mitochondrial oxidative phosphorylation. In addition to increased aerobic glycolysis, increased glycolysis is also seen in tumors that reach a size that exceeds the capacity of blood supply due to hypoxia. For a review of the Warburg theory and implications thereof, see, e.g., Chen et al., J. Bioenerg. Biomenzbr. (2007) 39:267-274.
Glucagon-like peptide-1 (GLP-1) is an important hormone and a fragment of the human proglucagon molecule. GLP-1 is rapidly metabolized by a peptidase (dipeptidylpeptidase IV or DPP-IV). A fragment of GLP-1, glucagon-like peptide-1 (7-36) amide (also known as GLP-1 (7-36) amide, glucagon-like insulinotropic peptide, or GLIP) is a gastrointestinal peptide that potentiates the release of insulin in physiologic concentrations (Gutniak et al., N Engl J Med (1992) 14:326(20):1316-22). Food intake, as well as stimulation of the sympathetic nervous system, stimulates secretion of GLP-1 in the small intestine of mammals. Further, GLP-1 stimulates the production and secretion of insulin, the release of somatostatin, glucose utilization by increasing insulin sensitivity, and, in animal studies, also stimulates beta-cell function and proliferation. GLP-1(7-36)amide and GLP-1(7-37) normalize fasting hyperglycemia in type 2 diabetic patients (Nauck, M. A., et al., Diabet. Med. 15(11):937-45 (1998)).
Exendin-4, a GLP-1 receptor agonist, is a molecule purified from Heloderma suspectuni venom (Eng, et al., Biol. Chem. (1992) 267:7402-7405) and shows structural relationship to the hormone GLP-1(7-36)amide. Exendin-4 and truncated exendin-(9-39)amide specifically interact with the GLP-1 receptor on insulinoma-derived cells and on lung membranes (Goke et al., J Biol. Chem. (1993) 268:19650-19655). Exendin-4 has approximately 53% identity to human GLP-1 (Pohl, et al., J. Biol. Chem. (1998) 273:9778-9784). Unlike GLP-1, however, exendin-4 is resistant to degradation by DPP-IV. A glycine substitution confers resistance to degradation by DPP-1V (Young, et al., Diabetes (1999) 48(5):1026-1034).
The increased dependency of cancer cells on the glycolytic pathway is an important metabolic difference between normal and malignant cells. The present invention provides a unique solution to disrupting cancer cell energy reliance on the glycolytic pathway.
The present invention relates to compositions, devices and methods for treating cancer. The invention utilizes GLP-1 receptor agonists to restrict glucose as an energy source for cancer cells and tumors. The GLP-1 receptor agonists can be used alone or in combination with other beneficial agents, such as anticancer agents, antidiabetic agents and the like, as well as in combination with anticancer treatment modalities, such as radiation, surgery and chemotherapeutic regimens.
Thus, in one aspect the invention relates to a method of treating cancer in a subject in need of such treatment, comprising administering a GLP-1 receptor agonist to said subject.
In certain aspects of the method, the GLP-1 receptor agonist is a glucagon-like peptide-1 (GLP-1), a derivative of GLP-1, or an analog of GLP-1. In some embodiments, the GLP-1 receptor agonist is GLP(7-36)amide comprising the sequence of SEQ ID NO:1.
In other aspects of the invention, the GLP-1 receptor agonist is exenatide, a derivative of exenatide, or an analog of exenatide, such as a synthetic exenatide peptide comprising the sequence of SEQ ID NO:2.
In additional aspects of the invention, the GLP-1 receptor agonist is selected from the group consisting of lixisenatide, liraglutide (VICTOZA™), albiglutide (SYNCRIA™) semaglutide, taspoglutide, BYETTA™, BYDUREON™ and LY2189265. In some embodiments, formulations comprising the GLP-1 receptor agonist are delivered by injection.
In further aspects, the GLP-1 receptor agonist is delivered using an implanted drug delivery device, such as an osmotic delivery device, that provides continuous delivery of a suspension formulation of GLP-1 receptor agonist for a period of at least one month.
In other aspects, the GLP-1 receptor agonist and/or other beneficial agent is provided in a suspension formulation comprising: (a) a particle formulation comprising said GLP-1 receptor agonist and/or beneficial agent; and (b) a vehicle formulation, wherein the particle formulation is dispersed in the vehicle.
In additional aspects, the suspension formulation may further comprise a particle formulation comprising a GLP-1 receptor agonist and/or beneficial agent and one or more stabilizers selected from the group consisting of carbohydrates, antioxidants, amino acids, buffers, and inorganic compounds. The suspension formulation further comprises a non-aqueous, single-phase suspension vehicle comprising one or more polymers and one or more solvents. The suspension vehicle typically exhibits viscous fluid characteristics and the particle formulation is dispersed in the vehicle.
In another embodiment, the suspension formulation comprises a particle formulation comprising a GLP-1 receptor agonist and/or a beneficial agent, a disaccharide (e.g., sucrose), methionine, and a buffer (e.g., citrate), and a non-aqueous, single-phase suspension vehicle comprising one or more pyrrolidone polymer (e.g., polyvinylpyrollidone) and one or more solvent (e.g., lauryl lactate, lauryl alcohol, benzyl benzoate, or mixtures thereof.
The particle formulations of the present invention may further comprise a buffer, for example, selected from the group consisting of citrate, histidine, succinate, and mixtures thereof.
The particle formulations of the present invention may further comprise an inorganic compound, for example, selected from the group consisting of citrate, histidine, succinate, and mixtures thereof. NaCl, Na2SO4, NaHCO3, KCl, KH2PO4, CaCl2, and MgCl2.
The one or more stabilizers in the particle formulations may comprise, for example, a carbohydrate selected from the group consisting of lactose, sucrose, trehalose, mannitol, cellobiose, and mixtures thereof.
The one or more stabilizers in the particle formulations may comprise, for example, a antioxidant selected from the group consisting of methionine, ascorbic acid, sodium thiosulfate, ethylenediaminetetraacetic acid (EDTA), citric acid, cysteins, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxanisol, butylated hydroxyltoluene, and propyl gallate, and mixtures thereof.
The one or more stabilizers in the particle formulations may comprise an amino acid.
In one embodiment, the solvent of the suspension vehicle of the present invention is selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof. An example of a polymer that can be used to formulate the suspension vehicle is a pyrrolidone (e.g., polyvinylpyrrolidone). In a preferred embodiment, the polymer is a pyrrolidone and the solvent is benzyl benzoate.
The suspension formulation typically has an overall moisture content less than about 10 wt % and in a preferred embodiment less than about 5 wt %.
In additional embodiments, a beneficial agent, such as an anticancer agent, in addition to the GLP-1 receptor agonist is delivered to said subject. In certain embodiments, the anticancer agent is a chemotherapeutic agent and/or an anticancer antibody. The additional beneficial agent can be delivered prior to, subsequent to or concurrent with the GLP-1 receptor agonist. In some embodiments, an implantable drug delivery device may be used to deliver formulations comprising an anticancer agent. In one embodiment, the device is an osmotic delivery device.
In some embodiments, implantable drug delivery devices deliver a GLP-1 receptor agonist formulations and/or other beneficial agent formulations at a substantially uniform rate for a period of about one month to about a year. Such devices may, for example, be implanted subcutaneously in convenient locations.
The present invention also includes methods of manufacturing the suspension formulations, particle formulations, suspension vehicles, and devices of the present invention as described herein.
These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.
All patents, publications, and patent applications cited in this specification are herein incorporated by reference as if each individual patent, publication, or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a GLP-1 receptor agonist” includes a combination of two or more such molecules, reference to “a peptide” includes one or more peptides, mixtures of peptides, and the like.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although other methods and materials similar, or equivalent, to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.
In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
The terms “peptide,” “polypeptide,” and “protein” are used interchangeably herein and typically refer to a molecule comprising a chain of two or more amino acids (e.g., most typically L-amino acids, but also including, e.g., D-amino acids, modified amino acids, amino acid analogs, and/or amino acid mimetic). Peptides may also comprise additional groups modifying the amino acid chain, for example, functional groups added via post-translational modification. Examples of post-translation modifications include, but are not limited to, acetylation, alkylation (including, methylation), biotinylation, glutamylation, glycylation, glycosylation, isoprenylation, lipoylation, phosphopantetheinylation, phosphorylation, selenation, and C-terminal amidation. The term peptide also includes peptides comprising modifications of the amino terminus and/or the carboxy terminus. Modifications of the terminal amino group include, but are not limited to, des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include, but are not limited to, amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications (e.g., wherein lower alkyl is C1-C4 alkyl).
The terminal amino acid at one end of the peptide chain typically has a free amino group (i.e., the amino terminus). The terminal amino acid at the other end of the chain typically has a free carboxyl group (i.e., the carboxy terminus). Typically, the amino acids making up a peptide are numbered in order, starting at the amino terminus and increasing in the direction of the carboxy terminus of the peptide.
The phrase “amino acid residue” as used herein refers to an amino acid that is incorporated into a peptide by an amide bond or an amide bond mimetic.
The term “GLP-1 receptor agonist” as used herein refers to an agent capable of binding and activating the GLP-1 receptor. The term includes GLP-1 hormones, as well as GLP-1 peptides, peptide analogs thereof, or peptide derivatives thereof. Also encompassed by the term GLP-1 receptor agonist are other molecules that are capable of binding and activating the GLP-1 receptor, such as without limitation, an exenatide peptide, a peptide analog thereof, or a peptide derivative thereof. Specific examples of preferred GLP-1 receptor agonists include exenatide having the amino acid sequence of exendin-4, GLP-1(7-36)amide, lixisenatide, liraglutide (VICTOZA™), albiglutide (SYNCRIA™), semaglutide, taspoglutide, BYETTA™, BYDUREON™ and LY2189265. The term also includes small molecules capable of binding and activating the GLP-1 receptor. See, e.g., Sloop et al., Diabetes (2010) 59:3099-3107.
The term “anticancer agent” refers to any agent that exhibits anti-tumor activity as defined below. Such agents include, without limitation, chemotherapeutic agents (i.e., a chemical compound or combination of compounds useful in the treatment of cancer), anticancer antibodies, agents that disrupt nucleic acid transcription and/or translation, such as antisense oligonucleotides, small interfering RNA (siRNA), and the like.
By “anti-tumor activity” is intended a reduction in the rate of cell proliferation, and hence a decline in growth rate of an existing tumor or in a tumor that arises during therapy, and/or destruction of existing neoplastic (tumor) cells or newly formed neoplastic cells, and hence a stabilization or decrease in the overall size of a tumor during therapy.
By “antidiabetic agent” is meant any agent that when administered to a subject either directly or indirectly causes a reduction in glucose levels. Such agents include, without limitation, agents for treating types 1 and 2 diabetes, such as but not limited to, GLP-1 receptor agonists; small molecules such as metformin, tolbutamide, glibenclamide, glipizide, gliquidone, glibornuride, tolazamide, sulfonylureas, meglitinides (e.g., repaglinide, and nateglinide); thiazolidinediones (TZDs), such as pioglitazone; SGLT1 and SGLT2 inhibitors; alpha glucosidase inhibitors; amylin (as well as synthetic analogs such as pramlintide); dipeptidyl peptidase IV (DPP-1V) inhibitors (e.g., saxagliptin, sitagliptin, alogliptin and vildagliptin); long/short acting insulins; glucagon receptor antagonists; GRP agonists (e.g., GRP-119 and GRP-40), and the like. Use of oral dipeptidyl peptidase-IV (DPP-IV or DPP-4) inhibitors orally to prevent cleavage of GLP-1 may be particularly useful when the formulation comprises a GLP-1 that is cleavable by dipeptidyl peptidase-1V (see, e.g., U.S. Pat. No. 7,205,409, incorporated herein by reference in its entirety).
An “antibody” intends a molecule that binds to an epitope of interest present in an antigen. The term “antibody” as used herein includes antibodies obtained from both polyclonal and monoclonal preparations, as well as, the following: hybrid (chimeric) antibody molecules (see, for example, Winter et al., Nature (1991) 349:293-299; and U.S. Pat. No. 4,816,567); F(ab′)2 and F(ab) fragments; Fv molecules (non-covalent heterodimers, see, for example, Inbar et al., Proc Natl Acad Sci USA (1972) 69:2659-2662; and Ehrlich et al., Biochem (1980) 19:4091-4096); single-chain Fv molecules (sFv) (see, for example, Huston et al., Proc Natl Acad Sci USA (1988) 85:5879-5883); dimeric and trimeric antibody fragment constructs; diabodies; avamers; aptamers; affitins; affitins; anticalins; affibody molecules; designed ankyrin repeat proteins; domain antibodies; minibodies (see, e.g., Pack et al., Biochem (1992) 31:1579-1584; Cumber et al., J Immunology (1992) 149B:120-126); humanized antibody molecules (see, for example, Riechmann et al., Nature (1988) 332:323-327; Verhoeyan et al., Science (1988) 239:1534-1536; and U.K. Patent Publication No. GB 2,276,169, published 21 Sep. 1994); and, any functional fragments obtained from such molecules, or fusions thereof, wherein such fragments and fusions retain immunological binding properties of the parent antibody molecule. Chimeric antibodies composed of human and non-human amino acid sequences may be formed from monoclonal antibody molecules to reduce their immunogenicity in humans (Winter et al. (1991) Nature 349:293; Lobuglio et al. (1989) Proc. Nat. Acad. Sci. USA 86:4220; Shaw et al. (1987) J Immunol. 138:4534; and Brown et al. (1987) Cancer Res. 47:3577; Rieclunann et al. (1988) Nature 332:323; Verhoeyen et al. (1988) Science 239:1534; and Jones et al. (1986) Nature 321:522; EP Publication No. 519,596, published 23 Dec. 1992; and U.K. Patent Publication No. GB 2,276,169, published 21 Sep. 1994).
As used herein, the term “monoclonal antibody” refers to an antibody composition having a homogeneous antibody population. The term is not limited regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made. The term encompasses whole immunoglobulins as well as fragments such as Fab, F(ab′)2, Fv, and other fragments, as well as chimeric and humanized homogeneous antibody populations, that exhibit immunological binding properties of the parent monoclonal antibody molecule.
As used herein, the term “anti-cancer antibody” encompasses antibodies that have been designed to target cancer cells, particularly cell-surface antigens residing on cells of a particular cancer of interest.
The term “vehicle” as used herein refers to a medium used to carry a compound, e.g., a drug. Vehicles of the present invention typically comprise components such as polymers and solvents. The suspension vehicles of the present invention typically comprise solvents and polymers that are used to prepare suspension formulations further comprising drug particle formulations.
The phrase “phase separation” as used herein refers to the formation of multiple phases (e.g., liquid or gel phases) in the suspension vehicle, such as when the suspension vehicle contacts the aqueous environment. In some embodiments of the present invention, the suspension vehicle is formulated to exhibit phase separation upon contact with an aqueous environment having less than approximately 10% water.
The phrase “single-phase” as used herein refers to a solid, semisolid, or liquid homogeneous system that is physically and chemically uniform throughout.
The term “dispersed” as used herein refers to dissolving, dispersing, suspending, or otherwise distributing a compound, for example, a peptide, in a suspension vehicle.
A “homogeneous suspension” typically refers to a particle that is insoluble in a suspension vehicle and is distributed uniformly in a suspension vehicle.
The phrase “chemically stable” as used herein refers to formation in a formulation of an acceptable percentage of degradation products produced over a defined period of time by chemical pathways, such as deamidation, (usually by hydrolysis), aggregation, or oxidation.
The phrase “physically stable” as used herein refers to formation in a formulation of an acceptable percentage of aggregates (e.g., dimers and other higher molecular weight products). Further, a physically stable formulation does not change its physical state as, for example, from liquid to solid, or from amorphous to crystal form.
The term “viscosity” as used herein typically refers to a value determined from the ratio of shear stress to shear rate (see, e.g., Considine, D. M. & Considine, G. D., Encyclopedia of Chemistry, 4th Edition, Van Nostrand, Reinhold, N.Y., 1984) essentially as follows:
F/A=μ*V/L (Equation 1)
From this relationship, the ratio of shear stress to shear rate defines viscosity. Measurements of shear stress and shear rate are typically determined using parallel plate rheometery performed under selected conditions (for example, a temperature of about 37° C.). Other methods for the determination of viscosity include, measurement of a kinematic viscosity using a viscometer, for example, a Cannon-Fenske viscometer, a Ubbelohde viscometer for the Cannon-Fenske opaque solution, or a Ostwald viscometer. Generally, suspension vehicles of the present invention have a viscosity sufficient to prevent particles suspended therein from settling during storage and use in a method of delivery, for example, in an implantable, drug delivery device.
The term “non-aqueous” as used herein refers to an overall moisture content, for example, of a suspension formulation, typically of less than or equal to about 10 wt %, preferably less than or equal to about 5 wt %, and more preferably less than about 4 wt %.
The term “subject” as used herein refers to any member of the subphylum chordata, including, without limitation, humans and other primates, including non-human primates such as rhesus macaque, chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.
The terms “drug,” “therapeutic agent”, and “beneficial agent” are used interchangeably to refer to any therapeutically active substance that is delivered to a subject to produce a desired beneficial effect. In one embodiment of the present invention, the drug is a GLP-1 receptor agonist, e.g., GLP-1 (7-36)amide, exenatide, and derivatives or analogs thereof. The devices and methods of the present invention are well suited for the delivery of polypeptides as well as small molecules and combinations thereof.
The term “osmotic delivery device” as used herein typically refers to a device used for delivery of one or more GLP-1 receptor agonists, or other beneficial agents to a subject, wherein the device comprises, for example, a reservoir (made, for example, from a titanium alloy) having a lumen that contains, in one chamber, a beneficial agent formulation (e.g., comprising one or more beneficial agent) and, in another chamber, an osmotic agent formulation. A piston assembly positioned in the lumen isolates the beneficial agent formulation from the osmotic agent formulation. A semi-permeable membrane (also termed a semi-permeable plug) is positioned at a first distal end of the reservoir adjacent the osmotic agent formulation. A diffusion moderator (which defines a delivery orifice through which the beneficial agent formulation exits the device) is positioned at a second distal end of the reservoir adjacent the suspension formulation. The piston assembly and the diffusion moderator define a chamber that contains the beneficial agent formulation and the piston assembly and the semipermeable membrane define a chamber that contains the osmotic agent formulation. The terms “flow modulator,” “diffusion modulator,” “flow moderator,” and “diffusion moderator” are used interchangeably herein. Typically, the osmotic delivery device is implanted within the subject, for example, subcutaneously (e.g., in the inside, outside, or back of the upper arm; or in the abdominal area). An exemplary osmotic delivery device is the DUROS™ delivery device.
Before describing the present invention in detail, it is to be understood that this invention is not limited to particular types of drug delivery, particular types of drug delivery devices, particular sources of peptides, particular solvents, particular polymers, and the like, as use of such particulars may be selected in view of the teachings of the present specification. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.
In one aspect, the present invention relates to methods of treating cancer in a subject in need of treatment, including, but not limited to, treating hematological tumors and solid tumors. The method comprises providing delivery of a GLP-1 receptor agonist formulation to a subject in need thereof. In certain embodiments, the GLP-1 receptor agonist formulation is delivered using an osmotic delivery device at a substantially uniform rate. The length of delivery of the formulation is determined based on the cancer being treated. In some embodiments, for example, the administration period is for at least about one month, at least about one month to about one year, at least about three months to about one year, at least about four months to about one year, at least about five months to about one year, at least about six months to about one year, at least about eight months to about one year, at least about nine months to about one year, or at least about 10 months to about one year. The period of administration can also exceed one year if necessary, such as from one year to two years. The method may further include subcutaneously inserting an osmotic delivery device, loaded with the GLP-1 receptor agonist formulation, into the subject.
In other embodiments of the invention, the GLP-1 receptor agonist is delivered parenterally (including by subcutaneous, intravenous, intramedullary, intraarticular, intramuscular, or intraperitoneal injection) rectally, topically, transdermally, intranasally, by inhalation, or orally (for example, in capsules, suspensions, or tablets). Injectable formulations of GLP-1 agonists are known and include, without limitation, lixisenatide, liraglutide (VICTOZA™), albiglutide (SYNCRIA™), semaglutide, taspoglutide, BYETTA™, BYDLIREON™ and LY2189265.
In one embodiment of the present invention the formulation comprises a glucagon-like peptide-1 (GLP-1), a derivative of GLP-1, or an analog of GLP-1.
In certain embodiments, the GLP-1 receptor agonist is GLP-1(7-36)amide shown in
In another embodiment of the present invention the formulation comprises exenatide, a derivative of exenatide, or an analog of exenatide. In certain embodiments, the exenatide is the exenatide peptide shown in
In certain embodiments, additional beneficial agents are provided with the GLP-1 receptor agonist formulations, such as anticancer agents, including without limitation, chemotherapeutic agents, anticancer antibodies, antisense nucleotides, siRNA, anticancer vaccines, and the like. Such additional beneficial agents are described in detail below. Administration of these agents is not limited to any particular delivery system and may include, without limitation, delivery using osmotic delivery devices as described herein if the agent is suitable for such delivery, or may be parenteral (including subcutaneous, intravenous, intramedullary, intraarticular, intramuscular, or intraperitoneal injection), rectal, topical, transdermal, intranasal, by inhalation, or oral (for example, in capsules, suspensions, or tablets). Administration of the additional agents to an individual may occur in a single dose or in repeat administrations, and in any of a variety of physiologically acceptable salt forms, and/or with an acceptable pharmaceutical carrier and/or additive as part of a pharmaceutical composition.
Physiologically acceptable salt forms and standard pharmaceutical formulation techniques and excipients are well known to persons skilled in the art (see, e.g., Physicians' Desk Reference (PDR) 2009, 63th ed. (PDR.net), Medical Economics Company; and Remington: The Science and Practice of Pharmacy, eds. Gennado et al., 21th ed, Lippincott, Williams & Wilkins, 2005). In certain embodiments, the GLP-1 receptor agonist and/or suitable additional beneficial agents, if present, are provided in a suspension formulation, comprising a particle formulation and a suspension vehicle. The particle formulation includes, but is not limited to, the GLP-1 receptor agonist or other agent of interest and one or more stabilizers. The one or more stabilizers are typically selected from the group consisting of carbohydrates, antioxidants, amino acids, and buffers. The suspension vehicle is typically a non-aqueous, single-phase suspension vehicle comprising one or more polymers and one or more solvents. The suspension vehicle exhibits viscous fluid characteristics. The particle formulation is uniformly dispersed in the vehicle.
The particle formulation of the present invention typically includes one or more of the following stabilizers: one or more carbohydrates (e.g., a disaccharide, such as, lactose, sucrose, trehalose, cellobiose, and mixtures thereof); one or more antioxidants (e.g., methionine, ascorbic acid, sodium thiosulfate, ethylenediaminetetraacetic acid (EDTA), citric acid, butylated hydroxyltoluene, and mixtures thereof); and one or more buffers (e.g., citrate, histidine, succinate, and mixtures thereof). In a preferred embodiment, the particle formulation comprises a GLP-1 receptor agonist, sucrose, methionine, and citrate buffer. The ratio of the GLP-1 receptor agonist to sucrose+methionine is typically about 1/20, about 1/10, about 1/5, about 1/2, about 2/1, about 5/1, about 10/1, or about 20/1, preferably between about 1/5 to 5/1, more preferably between about 1/3 to 3/1. The particle formulation is preferably a particle formulation prepared by spray drying and has a low moisture content, preferably less than or equal to about 10 wt %, more preferably less or equal to about 5 wt %. Alternatively, the particle formulation can be lyophilized.
The suspension vehicle for use in the present formulations comprises one or more solvents and one or more polymers. Preferably the solvent is selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof. More preferably the solvent is lauryl lactate or benzyl benzoate. Preferably the polymer is a pyrrolidone polymer. In some embodiments the polymer is polyvinylpyrrolidone (e.g., polyvinylpyrrolidone K-17, which typically has an approximate average molecular weight range of 7,900-10,800). In one embodiment, the solvent consists essentially of benzyl benzoate and polyvinylpyrrolidone.
The suspension formulation typically has a low overall moisture content, for example, less than or equal to about 10 wt % and in a preferred embodiment less than or equal to about 5 wt %.
2.1.0 Compositions and Formulations
2.1.1 GLP-1 Receptor Agonists
GLP-1, including three forms of the peptide, GLP-1(1-37), GLP-1(7-37) and GLP-1(7-36)amide, as well as peptide analogs of GLP-1 have been shown to stimulate insulin secretion (i.e., they are insulinotropic), which results in decreases in serum glucose concentrations (see, e.g., Mojsov, S., Int. J. Peptide Protein Research (1992) 40:333-343). The sequence of GLP-1(7-36)amide is shown in
Numerous GLP-1 peptide derivatives and peptide analogs demonstrating insulinotropic action are known in the art (see, e.g., U.S. Pat. Nos. 5,118,666; 5,120,712; 5,512,549; 5,545,618; 5,574,008; 5,574,008; 5,614,492; 5,958,909; 6,191,102; 6,268,343; 6,329,336; 6,451,974; 6,458,924; 6,514,500; 6,593,295; 6,703,359; 6,706,689; 6,720,407; 6,821,949; 6,849,708; 6,849,714; 6,887,470; 6,887,849; 6,903,186; 7,022,674; 7,041,646; 7,084,243; 7,101,843; 7,138,486; 7,141,547; 7,144,863; and 7,199,217, all of which are incorporated herein by reference in their entireties), as well as in clinical trials (e.g., taspoglutide and albiglutide). One example of a GLP-1 peptide derivative useful in the practice of the present invention is VICTOZA™ (liraglutide; U.S. Pat. Nos. 6,268,343, 6,458,924, 7,235,627, incorporated herein by reference in their entireties). Once-daily injectable VICTOZA™ (liraglutide) is commercially available in the United States, Europe, and Japan. Other injectable GLP-1 peptides for use with the present invention are described above and include, without limitation taspoglutide, albiglutide (SYNCRIA™), LY2189265 and semaglutide. For ease of reference the family of GLP-1 peptides, GLP-1 peptide derivatives and GLP-1 peptide analogs having insulinotropic activity is referred to collectively as “GLP-1.”
The molecule exenatide has the amino acid sequence of exendin-4 (Kolterman O. G., et al., J. Clin. Endocrinol. Metab. (2003) 88(7):3082-3089) and is produced by chemical synthesis or recombinant expression. Twice-daily injectable exenatide is commercially available in the United States and Europe, and sold under the tradename of BYETTA™. Another injectable exenatide under development is BYDUREON™. Exendin-3 and exendin-4 are known in the art and were originally isolated from Heloderma spp. (Eng, et al., J. Biol. Chem. (1990) 265:20259-62; Eng., et al., J. Biol. Chem. (1992) 267:7402-05). Numerous exenatide peptide derivatives and peptide analogs (including, e.g., exendin-4 agonists) are known in the art (see, e.g., U.S. Pat. Nos. 5,424,286; 6,268,343; 6,329,336; 6,506,724; 6,514,500; 6,528,486; 6,593,295; 6,703,359; 6,706,689; 6,767,887; 6,821,949; 6,849,714; 6,858,576; 6,872,700; 6,887,470; 6,887,849; 6,924,264; 6,956,026; 6,989,366; 7,022,674; 7,041,646; 7,115,569; 7,138,375; 7,141,547; 7,153,825; and 7,157,555, all of which are incorporated herein by reference in their entireties). One example of an exenatide derivative useful in the practice of the present invention is lixisenatide (see, e.g., U.S. Pat. No. 6,528,486, incorporated herein by reference in its entirety). For ease of reference herein, the family of exenatide peptides (e.g., including exendin-3, exendin-4, and exendin-4-amide), exenatide peptide derivatives, and exenatide peptide analogs is referred to collectively as “exenatide.”
2.1.2 Suspension Formulations
In one aspect, the present invention utilizes particle formulations of GLP-1 receptor agonists described above that can be used to prepare suspension formulations. The GLP-1 receptor agonists for use with the present invention shall not be limited by method of synthesis or manufacture and shall include those obtained from natural sources, or synthesized or manufactured by recombinant (whether produced from cDNA or genomic DNA), synthetic, transgenic, and gene-activated methods. In preferred embodiments of the present invention, the GLP-1 receptor agonist is a GLP-1 peptide or an exendin peptide (as described above), for example, GLP-1(7-36)amide or exenatide, such as the exenatide peptide shown in
Particle formulations are preferably chemically and physically stable for at least one month, preferably at least three months, more preferably at least six months, more preferably at least 12 months at delivery temperature. The delivery temperature is typically normal human body temperature, for example, about 37° C., or slightly higher, for example, about 40° C. Further, particle formulations are preferably chemically and physically stable for at least three months, preferably at least six months, more preferably at least 12 months, at storage temperature. Examples of storage temperatures include refrigeration temperature, for example, about 5° C., or room temperature, for example, about 25° C.
A particle formulation may be considered chemically stable if less than about 25%, preferably less than about 20%, more preferably less than about 15%, more preferably less than about 10%, and more preferably less than about 5% breakdown products of the peptide particles are formed after about three months, preferably after about six months, preferably after about 12 months at delivery temperature and after about six months, after about 12 months, and preferably after about 24 months at storage temperature.
A particle formulation may be considered physically stable if less than about 10%, preferably less than about 5%, more preferably less than about 3%, more preferably less than 1% aggregates of the peptide particles are formed after about three months, preferably after about six months, at delivery temperature and about 6 months, preferably about 12 months, at storage temperature.
To preserve protein stability, a GLP-1 receptor agonist solution is generally kept in a frozen condition and lyophilized or spray dried to a solid state. Tg (glass transition temperature) may be one factor to consider in achieving stable compositions of peptide. While not intending to be bound by any particular theory, the theory of formation of a high Tg amorphous solid to stabilize peptides, polypeptides, or proteins has been utilized in pharmaceutical industry. Generally, if an amorphous solid has a higher Tg, such as 100° C., peptide products will not have mobility when stored at room temp or even at 40° C. because the storage temperature is below the Tg. Calculations using molecular information have shown that if a glass transition temperature is above a storage temperature of 50° C. that there is zero mobility for molecules. No mobility of molecules correlates with no instability issues. Tg is also dependent on the moisture level in the product formulation. Generally, the more moisture, the lower the Tg of the composition.
Accordingly, in some aspects of the present invention, excipients with higher Tg may be included in the protein formulation to improve stability, for example, sucrose (Tg=75° C.) and trehalose (Tg=110° C.). Preferably, particle formulations are formable into particles using processes such as spray drying, lyophilization, desiccation, milling, granulation, ultrasonic drop creation, crystallization, precipitation, or other techniques available in the art for forming particles from a mixture of components. The particles are preferably substantially uniform in shape and size.
A typical spray dry process may include, for example, loading a spray solution containing a peptide, for example, GLP-1(7-36)amide or exenatide, and stabilizing excipients into a sample chamber. The sample chamber is typically maintained at a desired temperature, for example, refrigeration to room temperature. Refrigeration generally promotes stability of the protein. A solution, emulsion, or suspension is introduced to the spray dryer where the fluid is atomized into droplets. Droplets can be formed by use of a rotary atomizer, pressure nozzle, pneumatic nozzle, or sonic nozzle. The mist of droplets is immediately brought into contact with a drying gas in a drying chamber. The drying gas removes solvent from the droplets and carries the particles into a collection chamber. In spray drying, factors that can affect yield include, but are not limited to, localized charges on particles (which may promote adhesion of the particles to the spray dryer) and aerodynamics of the particles (which may make it difficult to collect the particles). In general, yield of the spray dry process depends in part on the particle formulation.
In one embodiment, the particles are sized such that they can be delivered via an implantable drug delivery device. Uniform shape and size of the particles typically helps to provide a consistent and uniform rate of release from such a delivery device; however, a particle preparation having a non-normal particle size distribution profile may also be used. For example, in a typical implantable osmotic delivery device having a delivery orifice, the size of the particles is less than about 30%, preferably is less than about 20%, more preferably is less than about than 10%, of the diameter of the delivery orifice. In an embodiment of the particle formulation for use with an osmotic delivery device, wherein the delivery orifice diameter of the implant is in a range of, for example, about 0.1 to about 0.5 mm, particle sizes may be preferably less than about 50 microns, more preferably less than about 10 microns, more preferably in a range from about 3 to about 7 microns. In one embodiment, the orifice is about 0.25 mm (250 microns) and the particle size is approximately 3-5 microns.
In a preferred embodiment, when the particles are incorporated in a suspension vehicle they do not settle in less than about three months at delivery temperature. Generally speaking, smaller particles tend to have a lower settling rate in viscous suspension vehicles than larger particles. Accordingly, micron- to nano-sized particles are typically desirable. In an embodiment of the particle formulation for use in an implantable osmotic delivery device, wherein the delivery orifice diameter of the implant is in a range of, for example, about 0.1 to about 0.5 mm, particle sizes may be preferably less than about 50 microns, more preferably less than about 10 microns, more preferably in a range from about 3 to about 7 microns.
In one embodiment, a particle formulation for use with the present invention comprises one or more GLP-1 receptor agonists, as described above and one or more stabilizers. The stabilizers may be, for example, carbohydrate, antioxidant, amino acid, buffer, or inorganic compound. The amounts of stabilizers in the particle formulation can be determined experimentally based on the activities of the stabilizers and buffers and the desired characteristics of the formulation. Typically, the amount of carbohydrate in the formulation is determined by aggregation concerns. In general, the carbohydrate level should not be too high so as to avoid promoting crystal growth in the presence of water due to excess carbohydrate unbound to insulinotropic peptide. Typically, the amount of antioxidant in the formulation is determined by oxidation concerns, while the amount of amino acid in the formulation is determined by oxidation concerns and/or formability of particles during spray drying. Typically, the amount of buffer components in the formulation is determined by pre-processing concerns, stability concerns, and formability of particles during spray drying. Buffer may be required to stabilize the GLP-1 receptor agonist during processing, e.g., solution preparation and spray drying, when all excipients are solubilized.
Examples of carbohydrates that may be included in the particle formulation include, but are not limited to, monosaccharides (e.g., fructose, maltose, galactose, glucose, D-mannose, and sorbose), disaccharides (e.g., lactose, sucrose, trehalose, and cellobiose), polysaccharides (e.g., raffinose, melezitose, maltodextrins, dextrans, and starches), and alditols (acyclic polyols; e.g., mannitol, xylitol, maltitol, lactitol, xylitol sorbitol, pyranosyl sorbitol, and myoinsitol). Preferred carbohydrates include non-reducing sugars, such as sucrose, trehalose, and raffinose.
Examples of antioxidants that may be included in the particle formulation include, but are not limited to, methionine, ascorbic acid, sodium thiosulfate, catalase, platinum, ethylenediaminetetraacetic acid (EDTA), citric acid, cysteins, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxanisol, butylated hydroxyltoluene, and propyl gallate.
Examples of amino acids that may be included in the particle formulation include, but are not limited to, arginine, methionine, glycine, histidine, alanine, L-leucine, glutamic acid, iso-leucine, L-threonine, 2-phenylamine, valine, norvaline, praline, phenylalanine, trytophan, serine, asparagines, cysteine, tyrosine, lysine, and norleucine. Preferred amino acids include those that readily oxidize, e.g., cysteine, methionine, and trytophan.
Examples of buffers that may be included in the particle formulation include, but are not limited to, citrate, histidine, succinate, phosphate, maleate, tris, acetate, carbohydrate, and gly-gly. Preferred buffers include citrate, histidine, succinate, and tris. It is to be understood that buffers can be added to the solution before formation of the particles, for example, by spray drying. However, after the dry particle formation is prepared, the buffer component no longer serves as a buffer in the dried particles. For ease of reference herein, when referring to buffer components, the term buffer is used.
Examples of inorganic compounds that may be included in the particle formulation include, but are not limited to, NaCl, Na2SO4, NaHCO3, KCl, KH2PO4, CaCl2, and MgCl2.
In addition, the particle formulation may include other excipients, such as but not limited to surfactants and salts. Examples of surfactants include, but are not limited to, Polysorbate 20, Polysorbate 80, PLURONIC™, F68, and sodium docecyl sulfate (SDS). Examples of other excipients include, but are not limited to, mannitol and glycine. Examples of salts include, but are not limited to, sodium chloride, calcium chloride, and magnesium chloride.
In one embodiment, the particle formulation comprises, for example, exenatide peptide, sucrose (carbohydrate), methionine (antioxidant), and sodium citrate/citric acid.
All components included in the particle formulation are typically acceptable for pharmaceutical use in mammals, in particular, in humans.
Particle size distribution of the dry particle powder can be well controlled (0.1 micron-20 micron), for example, by using the methods of spray drying or lyophilization to prepare the particle formulations. The process parameters for formation of the dry powder are optimal to produce particles with desired particle size distribution, density, and surface area.
The selected excipients and stabilizers in the particle formulation may provide, for example, the following functions: density modification of the dry powder; preservation of the peptide chemical stability; maintenance of the peptide's physical stability (e.g., high glass transition temperature, and avoiding phase to phase transition); producing homogenous dispersions in suspension; and modification of hydrophobicity and/or hydrophilicity to manipulate dry powder solubility in selected solvents.
See U.S. Patent Publication No. 2008/0260840, incorporated herein by reference in its entirety, for detailed methods of producing particle formulations.
In summary, GLP-1 receptor agonists can be formulated into dried powders in solid state, which preserves maximum chemical and biological stability of proteins or peptides. The particle formulation offers long term storage stability at high temperature, and therefore, allows delivery to a subject of stable and biologically effective peptide for extended periods of time.
Although the particle formulations described above are with reference to GLP-1 receptor agonists, such particle formulations can also be formed with any other suitable agents, such as other suitable beneficial polypeptides, including suitable anticancer polypeptides, antibodies and the like, described in detail below.
Suspension formulations for use with the present invention can be produced using particle formulations as described above. See U.S. Patent Publication No. 2008/0260840, incorporated herein by reference in its entirety, for detailed methods of producing such suspension formulations. In one aspect of the present invention, the suspension formulation includes a suspension vehicle to provide a stable environment in which the GLP-1 receptor agonist particle formulation (or other suitable particle formulation) is dispersed. The particle formulations are chemically and physically stable (as described above) in the suspension vehicle. The suspension vehicle typically comprises one or more polymers and one or more solvents that form a solution of sufficient viscosity to uniformly suspend the particles comprising the GLP-1 receptor agonist or other suitable agent. In addition to the GLP-1 receptor agonist, the suspension formulations can be used with any suitable agents, such as other suitable beneficial polypeptides, including suitable anticancer polypeptides, antibodies and the like, described in detail below.
The viscosity of the suspension vehicle is typically sufficient to prevent the particle formulation from settling during storage and use in a method of delivery, for example, in an implantable, drug delivery device. The suspension vehicle is biodegradable in that the suspension vehicle disintegrates or breaks down over a period of time in response to a biological environment. The disintegration of the suspension vehicle may occur by one or more physical or chemical degradative processes, such as by enzymatic action, oxidation, reduction, hydrolysis (e.g., proteolysis), displacement (e.g., ion exchange), or dissolution by solubilization, emulsion or micelle formation. After the suspension vehicle disintegrates, components of the suspension vehicle are absorbed or otherwise dissipated by the body and surrounding tissue of the patient.
The solvent in which the polymer is dissolved may affect characteristics of the suspension formulation, such as the behavior of the particle formulation during storage. A solvent may be selected in combination with a polymer so that the resulting suspension vehicle exhibits phase separation upon contact with the aqueous environment. In some embodiments, the solvent may be selected in combination with the polymer so that the resulting suspension vehicle exhibits phase separation upon contact with the aqueous environment having less than approximately about 10% water.
The solvent may be an acceptable solvent that is not miscible with water. The solvent may also be selected so that the polymer is soluble in the solvent at high concentrations, such as at a polymer concentration of greater than about 30%. However, typically particles comprising the GLP-1 receptor agonists are substantially insoluble in the solvent. Examples of solvents useful in the practice of the present invention include, but are not limited to, lauryl alcohol, benzyl benzoate, benzyl alcohol, lauryl lactate, decanol (also called decyl alcohol), ethyl hexyl lactate, and long chain (C8 to C24) aliphatic alcohols, esters, or mixtures thereof. The solvent used in the suspension vehicle may be “dry,” in that it has a low moisture content. Preferred solvents for use in formulation of the suspension vehicle include lauryl lactate, lauryl alcohol, benzyl benzoate, and combinations thereof.
Examples of polymers for formulation of the suspension vehicles include, but are not limited to, a polyester (e.g., polylactic acid or polylacticpolyglycolic acid), pyrrolidone polymer (e.g., polyvinylpyrrolidone (PVP) having a molecular weight ranging from approximately 2,000 to approximately 1,000,000), ester or ether of an unsaturated alcohol (e.g., vinyl acetate), polyoxyethylenepolyoxypropylene block copolymer, or mixtures thereof. In one embodiment, the polymer is PVP having a molecular weight of 2,000 to 1,000,000. In a preferred embodiment the polymer is polyvinylpyrrolidone K-17 (typically having an approximate average molecular weight range of 7,900-10,800). Polyvinylpyrrolidone can be characterized by its K-value (e.g., K-17), which is a viscosity index. The polymer used in the suspension vehicle may include one or more different polymers or may include different grades of a single polymer. The polymer used in the suspension vehicle may also be dry or have a low moisture content.
Generally speaking, a suspension vehicle according to the present invention may vary in composition based on the desired performance characteristics. In one embodiment, the suspension vehicle may comprise about 40% to about 80% (w/w) polymer(s) and about 20% to about 60% (w/w) solvent(s). Preferred embodiments of a suspension vehicle include vehicles formed of polymer(s) and solvent(s) combined at the following ratios: about 25% solvent and about 75% polymer; about 50% solvent and about 50% polymer; about 75% solvent and about 25% polymer.
The suspension vehicle may exhibit Newtonian behavior. The suspension vehicle is typically formulated to provide a viscosity that maintains a uniform dispersion of the particle formulation for a predetermined period of time. This helps facilitate making a suspension formulation tailored to provide controlled delivery of the insulinotropic peptide at a desired rate. The viscosity of the suspension vehicle may vary depending on the desired application, the size and type of the particle formulation, and the loading of the particle formulation in the suspension vehicle. The viscosity of the suspension vehicle may be varied by altering the type or relative amount of the solvent or polymer used.
The suspension vehicle may have a viscosity ranging from about 100 poise to about 1,000,000 poise, preferably from about 1,000 poise to about 100,000 poise. The viscosity may be measured at a selected temperature, for example, 33° C., at a shear rate of 10.sup.−4/sec, using a parallel plate rheometer. In some embodiments, the viscosity of the suspension vehicle ranges from approximately 5,000 poise to approximately 50,000 poise, such as about 7,000 poise to about 40,000 poise, about 8,000 poise to about 20,000 poise, about 9,000 poise to about 25,000 poise, about 10,000 poise to about 20,000 poise, and the like. In preferred embodiments, the viscosity range is between about 12,000 to about 18,000 poise at 33° C.
The suspension vehicle may exhibit phase separation when contacted with the aqueous environment; however, typically the suspension vehicle exhibits substantially no phase separation as a function of temperature. For example, at a temperature ranging from approximately 0° C. to approximately 70° C. and upon temperature cycling, such as cycling from 4° C. to 37° C. to 4° C., the suspension vehicle typically exhibits no phase separation.
The suspension vehicle may be prepared by combining the polymer and the solvent under dry conditions, such as in a dry box. The polymer and solvent may be combined at an elevated temperature, such as from approximately 40° C. to approximately 70° C., and allowed to liquefy and form the single phase. The ingredients may be blended under vacuum to remove air bubbles produced from the dry ingredients. The ingredients may be combined using a conventional mixer, such as a dual helix blade or similar mixer, set at a speed of approximately 40 rpm. However, higher speeds may also be used to mix the ingredients. Once a liquid solution of the ingredients is achieved, the suspension vehicle may be cooled to room temperature. Differential scanning calorimetry (DSC) may be used to verify that the suspension vehicle is a single phase. Further, the components of the vehicle (e.g., the solvent and/or the polymer) may be treated to substantially reduce or substantially remove peroxides (e.g., by treatment with methionine; see, e.g., U.S. Patent Application Publication No. 2007-0027105, incorporated herein by reference in its entirety).
The particle formulation, comprising a GLP-1 receptor agonist, or other suitable agent, is added to the suspension vehicle to form a suspension formulation. The suspension formulation may be prepared by dispersing the particle formulation in the suspension vehicle. The suspension vehicle may be heated and the particle formulation added to the suspension vehicle under dry conditions. The ingredients may be mixed under vacuum at an elevated temperature, such as from about 40° C. to about 70° C. The ingredients may be mixed at a sufficient speed, such as from about 40 rpm to about 120 rpm, and for a sufficient amount of time, such as about 15 minutes, to achieve a uniform dispersion of the particle formulation in the suspension vehicle. The mixer may be a dual helix blade or other suitable mixer. The resulting mixture may be removed from the mixer, sealed in a dry container to prevent water from contaminating the suspension formulation, and allowed to cool to room temperature before further use, for example, loading into an implantable, drug delivery device, unit dose container, or multiple-dose container.
The suspension formulation typically has an overall moisture content of less than about 10 wt %, preferably less than about 5 wt %, and more preferably less than about 4 wt %.
The suspension formulations of the present invention are exemplified herein below with reference to exenatide and GLP-1(7-36)amide as representative GLP-1 receptor agonists (see, Example 3 and Example 4). These examples are not intended to be limiting.
In summary, the components of the suspension vehicle provide biocompatibility. Components of the suspension vehicle offer suitable chemico-physical properties to form stable suspensions of, for example, dry powder particle formulations. These properties include, but are not limited to, the following: viscosity of the suspension; purity of the vehicle; residual moisture of the vehicle; density of the vehicle; compatibility with the dry powders; compatibility with implantable devices; molecular weight of the polymer; stability of the vehicle; and hydrophobicity and hydrophilicity of the vehicle. These properties can be manipulated and controlled, for example, by variation of the vehicle composition and manipulation of the ratio of components used in the suspension vehicle.
The suspension formulations described herein may be used in an implantable, drug delivery device to provide sustained delivery of a compound over an extended period of time, such as over weeks, months, or up to about one year. Such an implantable drug delivery device is typically capable of delivering the compound at a desired flow rate over a desired period of time. The suspension formulation may be loaded into the implantable, drug delivery device by conventional techniques.
The suspension formulation may be delivered, for example, using an osmotically, mechanically, electromechanically, or chemically driven drug delivery device. The active agent in the suspension formulation is delivered at a flow rate that is therapeutically effective to the subject in need of treatment.
The active agent, such as GLP-1(7-36)amide, exenatide, or other suitable beneficial agent, may be delivered over a period ranging from more than about one week to about one year or more, preferably for about one month to about a year or more, more preferably for about three months to about a year or more. The implantable, drug delivery device may include a reservoir having at least one orifice through which the agent is delivered. The suspension formulation may be stored within the reservoir. In one embodiment, the implantable, drug delivery device is an osmotic delivery device, wherein delivery of the drug is osmotically driven. Some osmotic delivery devices and their component parts have been described, for example, the DUROS™ delivery device or similar devices (see, e.g., U.S. Pat. Nos. 5,609,885; 5,728,396; 5,985,305; 5,997,527; 6,113,938; 6,132,420; 6,156,331; 6,217,906; 6,261,584; 6,270.787; 6,287,295; 6,375,978; 6,395,292; 6,508,808; 6,544,252; 6,635,268; 6,682,522; 6,923,800; 6,939,556; 6,976,981; 6,997,922; 7,014,636; 7,207,982; 7,112,335; 7,163,688; U.S. Patent Publication Nos. 2005-0175701, 2007-0281024, and 2008-0091176, all of which are incorporated herein by reference in their entireties).
The DUROS™ delivery device typically consists of a cylindrical reservoir which contains the osmotic engine, piston, and drug formulation. The reservoir is capped at one end by a controlled-rate water-permeable membrane and capped at the other end by a diffusion moderator through which drug formulation is released from the drug reservoir. The piston separates the drug formulation from the osmotic engine and utilizes a seal to prevent the water in the osmotic engine compartment from entering the drug reservoir. The diffusion moderator is designed, in conjunction with the drug formulation, to prevent body fluid from entering the drug reservoir through the orifice.
The DUROS™ device releases a therapeutic agent at a predetermined rate based on the principle of osmosis. Extracellular fluid enters the DUROS™ device through a semi-permeable membrane directly into a salt engine that expands to drive the piston at a slow and even delivery rate. Movement of the piston forces the drug formulation to be released through the orifice or exit port at a predetermined sheer rate. In one embodiment, the reservoir of the DUROS™ device is loaded with a suspension formulation comprising, for example, GLP-1(7-36)amide or exenatide, wherein the device is capable of delivering the suspension formulation to a subject over an extended period of time (e.g., about one, about two, about three, about six, or about 12 months) at a predetermined, therapeutically effective delivery rate.
Other implantable, drug delivery devices may be used in the practice of the present invention and may include regulator-type implantable pumps that provide constant flow, adjustable flow, or programmable flow of the compound, such as those available from Codman & Shurtleff, Inc. (Raynham, Mass.), Medtronic, Inc. (Minneapolis, Minn.), and Tricumed Medinzintechnik GmbH (Germany).
Implantable devices, for example, the DUROS™ device, provide the following advantages for administration of the formulations of the present invention: true zero-order release of the insulinotropic peptide pharmacokinetically; long-term release period time (e.g., up to about 12 months); and reliable delivery and dosing of the GLP-1 receptor agonist or other suitable beneficial agent.
Fluid is imbibed into the chamber 20 through the semi-permeable membrane 18. The beneficial agent formulation is dispensed from the chamber 16 through the delivery orifice 24 in the diffusion moderator 22. The piston assembly 14 engages and seals against the interior wall of the reservoir 12, thereby isolating the osmotic agent formulation in chamber 20 and fluid imbibed through the semi-permeable membrane 18 from the beneficial agent formulation in chamber 16. At steady-state, the beneficial agent formulation is expelled through the delivery orifice 24 in the diffusion moderator 22 at a rate corresponding to the rate at which external fluid is imbibed into the chamber 20 through the semi-permeable membrane 18.
The semi-permeable membrane 18 may be in the form of a plug that is resiliently engaged in sealing relationship with the interior surface of the reservoir 12. In
The amount of beneficial agent employed in the delivery device of the invention is that amount necessary to deliver a therapeutically effective amount of the agent to achieve the desired therapeutic result. In practice, this will vary depending upon such variables, for example, as the particular agent, the site of delivery, the severity of the condition, and the desired therapeutic effect. Typically, for an osmotic delivery device, the volume of a beneficial agent chamber comprising the beneficial agent formulation is between about 100 μl to about 1000 μl, more preferably between about 120 μl and about 500 μl, more preferably between about 150 μl and about 200 μl.
Typically, the osmotic delivery device is implanted within the subject, for example, subcutaneously. The device(s) can be inserted in either or both arms (e.g., in the inside, outside, or back of the upper arm) or into the abdomen. Preferred locations in the abdomen are under the abdominal skin in the area extending below the ribs and above the belt line. To provide a number of locations for insertion of one or more osmotic delivery devices within the abdomen, the abdominal wall can be divided into 4 quadrants as follows: the upper right quadrant extending 5-8 centimeters below the right ribs and about 5-8 centimeters to the right of the midline, the lower right quadrant extending 5-8 centimeters above the belt line and 5-8 centimeters to the right of the midline, the upper left quadrant extending 5-8 centimeters below the left ribs and about 5-8 centimeters to the left of the midline, and the lower left quadrant extending 5-8 centimeters above the belt line and 5-8 centimeters to the left of the midline. This provides multiple available locations for implantation of one or more devices on one or more occasions.
The suspension formulation may also be delivered from a drug delivery device that is not implantable or implanted, for example, an external pump such as a peristaltic pump used for subcutaneous delivery in a hospital setting.
The suspension formulations of the present invention may also be used in infusion pumps, for example, the ALZET™ osmotic pumps which are miniature, infusion pumps for the continuous dosing of laboratory animals (e.g., mice and rats).
The suspension formulations of the present invention may also be used in the form of injections to provide highly concentrated bolus doses of biologically active agents, such as the GLP-1 receptor agonists, anti-cancer agents, etc.
The GLP-1 receptor agonists, such as GLP-1(7-36)amide and exenatide, can be delivered to a patient as a single modality treatment or in combination with other beneficial agents, including anticancer agents as described below, chemotherapeutic drugs, anticancer antibodies, antisense molecules, siRNA, and the like.
For example, one useful combination is with a tyrosine kinase inhibitor, such as SUTENT™, NEXAVAR™, BIBF 1120, ZD1839 (gefitinib), erlotinib, TYKERB™, and the like.
mTOR inhibitors, such as rapamycin (sirolimus), AZD8055, NVP-BEZ235, deforolimus, everolimus, temsirolimus, GSK1059615, WYE354, KU0063794, XL765 (all available from Selleck Chemicals) will also find use in a combination treatment.
Other drugs for use in combination with the GLP-1 receptor agonists (e.g., exenatide and GLP-1(7-36)amide), are those that cause hypoxia in tumor tissues, such as metformin, and drugs that inhibit the hypoxia inducible factor 1 such as CCAA/enhancer binding protein a, PX-478, resveratrol, and the various small molecule inhibitors described in Jones et al., Mol. Cancer. Ther. (2006) 5:2193-2202.
Also useful are drugs that inhibit IGF-1, such as octreonide acetate and tyrosine kinase inhibitors, that serve to block IGF-1 receptor signaling.
VEGF-inhibitors, such as anti-VEGF antibodies including bevacizumab) (AVASTIN™, as well as prolactin, sunitinib and sorafenib, may also be used in combination with the GLP-1 receptor agonists.
Another useful combination therapy is the use of a sugar analog, such as 2DG, subsequent to reducing glucose availability to the cancer cells using GLP-1 receptor agonists, such as exenatide and GLP-1(7-36)amide.
Cell cycle blockers will also find use herein, such as a cyclin-dependent kinase (cdk)-inhibitor, e.g., olomoucin, butyrolactone-I, n-butyrate, upregulators of cdk activity, e.g., flavopiridol, Chalcones (1,3-diphenylpropen-1-ones) and derivatives thereof.
The histone deacetylase (HDAC) enzyme SIRT-1 and other related sirtuin proteins, analogs and derivatives thereof will also find use herein.
Also useful are peptides that induce cell apoptosis, such TRAIL, antagonists or antibodies against integrin .alpha.v.beta.3, anti-survivin antibodies and antagonists of survivin, and numerous pro-apoptotic peptides, well known in the art, such as described in Ellerby et al., Nat. Med. (1999) 5:1032-1038.
Examples of cytokines which can be administered in a combination treatment include G-CSF, GM-CSF, M-CSF, IL-1.alpha., IL-1.beta., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-18, IL-21, IL-23, IFN-.alpha., IFN-.beta., IFN-.gamma., IFN-.lamda., MIP-1.alpha., MIP-1.beta., TGF-.beta., TNF.alpha., and TNF-.beta.
Examples of chemokines which can be administered include BCA-1/BLC, BRAK, Chemokine CC-2, CTACK, CXCL-16, ELC, ENA, ENA-70, ENA-74, ENA-78, Eotaxin, Exodus-2, Fractalkine, GCP-2, GRO, GRO alpha (MGSA), GRO-beta, GRO-gamma, HCC-1, HCC-4, 1-309, IP-10, 1-TAC, LAG-1, LD78-beta, LEC/NCC-4, LL-37, Lymphotactin, MCP, MCAF (MCP-1), MCP-2, MCP-3, MCP-4, MDC, MDC, MDC-2, MDC-4, MEC/CCL28, MIG, MIP, MIP-1 alpha, MIP-1 beta, MIP-1 delta, MIP-3/MPIF-1, MIP-3 alpha, MIP-3 bet, MIP-4 (PARC), MIP-5, NAP-2, PARC PF-4, RANTES, RANTES-2, SDF-1 alpha, SDF-1 beta, TARC, and TECK.
Examples of growth factors which can be delivered include Human Amphiregulin, Human Angiogenesis Proteins, Human ACE, Human Angiogenin, Human Angiopoietin, Human Angiostatin, Human Endostatin, Human Betacellulin, Human BMP, Human BMP-13/CDMP-2, Human BMP-14/CDMP-1, Human BMP-2, Human BMP-3, Human BMP-4, Human BMP-5, Human BMP-6, Human BMP-7, Human BMP-8, Human BMP-9, Human Colony Stimulating Factors, Human flt3-Ligand, Human G-CSF, Human GM-CSF, Human M-CSF, Human Connective Tissue Growth Factor, Human Cripto-1, Human Cryptic, Human ECGF, Human EGF, Human EG-VEGF, Human Erythropoietin, Human Fetuin, Human FGF, Human FGF-1, Human FGF-10, Human FGF-16, Human FGF-17, Human FGF-18, Human FGF-19, Human FGF-2, Human FGF-20, Human FGF-3, Human FGF-4, Human FGF-5, Human FGF-6, Human FGF-7/KGF, Human FGF-8, Human FGF-9, Human FGF-acidic, Human FGF-basic, Human GDF-11, Human GDF-15, Human Growth Hormone Releasing Factor, Human HB-EGF, Human Heregulin, Human HGF, Human IGF, Human IGF-1, Human IGF-11, Human Inhibin, Human KGF, Human LCGF, Human LIF, Human Miscellaneous Growth Factors, Human MSP, Human Myostatin, Human Myostatin Propeptide, Human Nerve Growth Factor, Human Oncostatin M, Human PD-ECGF, Human PDGF, Human PDGF (AA Homodimer), Human PDGF (AB Heterodimer), Human PDGF (BB Homodimer), Human PDGF (CC Homodimer), Human PLGF, Human PLGF-1, Human PLGF-2, Human SCF, Human SMDF, Human Stem Cell Growth Factor, Human SCGF-alpha, Human SCGF-beta, Human Thrombopoietin, Human Transforming Growth Factor, Human TGF-alpha, and Human TGF-beta.
In some embodiments, chemotherapeutic agents used in the methods of the invention are selected from antimetabolites; enzyme inhibitors including topoisomerase I and II inhibitors, tyrosine and serine/threonine kinase inhibitors and COX2 inhibitors, tubulin binders, proteasome inhibitors, anticancer alkylating agents including bifunctional and monofunctional alkylating agents and methylating agents, anticancer antibiotics, anticancer antibodies and active fragments and fusions thereof and antibody-drug conjugates, bisphosphonates, antiestrogens and antiandrogens, anticancer cytokines, anticancer enzymes, immunomodulatory agents, anticancer peptides, anticancer retinoids, anticancer steroids and related agents, anticancer phototherapeutics, normal tissue protectors and antihormonal agents including aromatase inhibitors.
Antimetabolites may include folate analogs, which inhibit dihydrofolate reductase resulting in DNA breaks by blocking purine and thymidylate synthesis. Examples of folate analogs include methotrexate (FOLEX™), trimetrexate (NEUTREXIN™) and pemetrexed (ALIMTA™). Other anitmetabolites are nucleoside analogs that disrupt DNA or RNA synthesis, such as purine or pyrimidine analogs. Examples of purine analogs include allopurinol (ZYLOPRIM™), mercaptopurine (PURINETHOL™), fludarabine (FLUDARA™), thioguanine (6-TG), cladribine (LEUSTATIN™, 2-CdA), and pentostatin (NIPENT™). Examples of pyrimidine analogs include capecitabine (XELODA™), cytarabine (CYTOSAR™), liposomal cytarabine (DEPOCYT™), floxuridine (FUDR™), fluororouracil (ADRUCIL™), gemcitabine (GEMZAR™), and clofarabine (CLOLAR™), decitabine (DACOGEN™) and azacitadine (VIDAZA™).
Topoisomerase II inhibitors bind to topoisomerase II and DNA, preventing the resealing of DNA strands during replication, and leading to DNA strand breaks, such as epipodophyllotoxins. Examples of epipodophyllotoxins include etoposide (VEPESID™, ETOPOPHOS™) and teniposide (VUMON™, VM26™). Alternatively, topoisomerase II inhibitors, such as anthracycline antibiotics, intercalate between DNA base pairs leading to free radicals and also topoisomerase II inhibition. Examples of anthracyclines include daunorubicin (DANOIJXOME™, CERUBIDINE™), liposomal daunorubicin (DAUNOXOME™), doxorubicin (ADRIAMYCIN™, RUBEX™), liposomal doxorubicin (DOXIL™), epirubicin (ELLENCE™), valrubicin (VALSTAR™), and idarubicin (IDAMYCIN™). Mitoxantrone (NOVANTRONE™) also inhibits topoisomerase II and is an anticancer therapeutic.
Topoisomerase I inhibitors bind to topoisomerase I and DNA, preventing DNA strand breaks, such as, e.g., camptothecins, including irinotecan (CAMPTOSAR™) and topotecan (HYCAMTIN™).
Anticancer kinase inhibitors inhibit phosphorylation of a protein or small molecule messenger in a an intracellular signaling pathway in malignant cells or vascular or stromal cells, such as, e.g., imatinib mseylate (GLEEVEC™), gefitinib (IRESSA™) or erlotinib (TARCEVA™), sorafenib (NEXAVAR™), sunitinib (SUTENT™), nilotinib (TASIGN™), everolimus (AFINITOR™), lapatinib (TYKERB™), dasatinib (SPRYCEL™), BRAF inhibitors such as GSK218436 (GlaxoSmithKline, London UK) and vemurafenib (Plexxikon Inc., CA) and MEK inhibitors.
Tubulin binders include agents that bind to microtubules, shift the microtubules toward polymerization, and are active in the M phase, such as taxanes including docetaxel (TAXOTERE™) and paclitaxel (TAXOL™) and epothilones including ixabepilone (IXEMPRA™) and eribulin mesylate. Other tubulin binders act by inhibiting polymerization and mitotic spindle formation, and are active in the S phase, such as, e.g., vinca alkaloids, including vinblastine (VELBAN™), vincristine (ONCOVIN™), and vinorelbine (NAVELBINE™). Other tubulin binders include ILX-651 (TASIDOTIN™) and estramustine (EMCYT™), which inhibit microtubule assembly and disassembly.
Proteasome inhibitors block the trypsin-like, chymotrypsin-like and/or peptidylglutamyl peptide hydrolyzing-like protease activities in nuclear and cytoplasmic proteasomes. Examples of proteasome inhibitors include bortezomib (VELCADE™).
Anticancer alkylating agents are reactive molecules that bind to DNA and interfere with DNA replication. These agents include, but are not limited to, alkyl sulfonates such as busulfan (MYLERAN™), platinum analogs such as carboplatin (PARAPLATIN™), cisplatin (PLATINOL™-AQ, and oxaliplatin (ELOXATIN™), nitrosoureas such as carmustine (BICNU™), lomustine (CCNU™, CEENU™), and streptozocin (ZANOSAle), nitrogen mustards including chlorambucil (LEUKERAN™), uracil mustard, cyclophosphamide (CYTOXAN™), ifosfamide (IFEX™), meclorethamine (MUSTARGEN™), and melphalan (ALKERAN™, L-PAM), bendamustine (TREANDA™), triazenes such as dacarbazine (DTIC-DOME™), procarbazine (MATULANE™), temozolomide (TEMODAR™), ethylenimines including hexamethylamine (HEXALEN™), and thiotepa (THIOPLEX™), hydroxyurea (HYDREA™, arsenic trioxide (TRISENOX™), mitomycin C (MUTAMYCIN™, MITOZYTREX™) and trabectedin (YONDELIS™).
Anticancer antibiotics act by a variety of mechanisms including inhibition of protein synthesis generation of oxygen free radicals in the vicinity of DNA and other mechanisms. Examples of anticancer antibiotics include actinomycin D (COSMEGEN™), bleomycin sulfate (BLENOXANE™) and plicamycin (MITHRACIN™).
Anticancer antibodies bind to specific molecular targets on cells or in the extracellular space. Anticancer antibodies act by neutralizing the activity of the target, attracting immune cells to the target cell or by being directly or indirectly cytotoxic toward the target cell. Anticancer antibodies include, but are not limited to, anti-CD52 antibodies such as alemtuzumab (CAMPATH™); anti-VEGF antibodies including bevacizumab (AVASTIN™); anti-CD33 antibodies, including gemtuzumab ozogamicin (MYLOTARG™); anti-CD20 antibodies including ibritumomab (ZEVALIN™), rituximab (RITUXAN™), tositumomab (BEXXAR™) and ofatumumab (ARZERRA™); anti-EGFR antibodies such as cetuximab (ERBITUX™) and panitumumab (VECTIBEX™); anti-Her2 antibodies, including trastuzumab (HERCEPTIN™); anti-CTLA4 antibodies including Ipilimumab (YERVOY™); adnectins; and domain antibodies. Active fragments and fusions of these antibodies will also find use herein.
Anticancer cytokines include, but are not limited to, aldesleukin (PROLEUKIN™), denileukin diftitox (ONTAK™), GM-CSF (sargramostim, PROKINE™, LEUKINE™), interferon alfa-2b (INTRON™-A), PEGinterferon alpha (PEGASYS™ or PEGINTRON™) and consensus interferon (INFERGEN™).
Immunomodulatory agents are effective by increasing the response of the immune system of the host to the malignancy. Immunomodulatory agents include, but are not limited to, Bacillus Calmette-Gurerin (BCG Vaccine), levamisole (ERGAMISOL™), thalidomide (THALIDOMID™), sipuleucel-T (PROVENGE™), and lenalidomide (REVLIMID™).
Anticancer retinoids include, but are not limited to, aliretinoin (PANRETIN™), bexarotene (TARGRETIN™) and tretinoin (VESANOID™, ATRA™); other agents include octreotide acetate (SANDOSTATIN™).
Anticancer enzymes include asparaginase (ELSPAR™), pegademase (ADAGEN™), and pegaspargase (ONCASPAR™).
Anticancer steroids and related agents include dexamethasone (DECADRON™), predisone (DELTASONE™), prednisolone (DELTA-CORTEF™) and mitotane (LYSODREN™).
Normal tissue protectors include, but are not limited to, amifostine (ETHYOL™), darbepoetin alfa (ARANESP™), dexrazoxane (ZINECARD™), epoetin alfa (EPOGEN™, PROCRIT™), filgrastim (NEUPOGEN™), folinic acid (leucovorin), allopurinol (ALOPRIM™) mesna (MESNEX™), oprelvekin (NEUMEGA™), pegfilgrastim (NEULASTA™), GM-CSF (sargramostim, PROKINE™, LEUKINE™), raloxifene (EVISTA™) and eltrombopag (PROMACTA™).
Phototherapeutics are agents that sensitize cells so that exposure to a specific frequency of laser light induces abundant free radical formation and DNA alkylation. These agents include, but are not limited to, porfimer sodium (PHOTOFRIN™).
Antihormones include LHRH agonists, which compete with gonadotropin by binding to the hypothalamus causing an initial surge of LH and FSH followed by down regulation by negative feedback, including goserelin (ZOLADEX™), leuprolide (LUPRON™ or ELIGARD™), and triptorelin (TRELSTAR™); and antiandrogens, which competitively bind and inhibit the binding of androgens to androgen receptors, such as hicalutamide (CASODEX™), flutamide (EULEXIN™), nilutamide (NILANDRON™), aminoglutethimide (CYTADREN™), and abarelix (PLENAXIS™); and antiestrogens, which competitively bind and inhibit the binding of estrogens to estrogen receptors such as tamoxifen (NOLVADEX™), fluoxymesterone (HALOTESTIN™) and megestrol (MEGACE™), bisphosphonates including pamidronate (AREDIA™) and zoledronate (ZOMETA™), and aromatase inhibitors including anastrozole (ARIMIDEX™), exemestane (AROMASIN™), fulvestrant (FASLODEX™), and letrozole (FEMARA™), androgen biosynthesis inhibitors such as abiraterone acetate (ZITIGA™), androgen signaling inhibitor such as MDV 3100.
ATP-competitive inhibitors of c-Met/HGF receptor and/or the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) include crizotinib, CH5424802 (Chugai Pharmaceutical Co., Ltd., Japan), and AP26113 (ARIAD Pharmaceuticals, Inc., MA).
Exemplary agents including beneficial agents and anticancer agents that can be delivered with the GLP-1 receptor agonist compositions described herein include those described above and/or shown in Table 1.
Treatment will depend on the cancer in question. Tests can be performed prior to treatment to specifically tailor a treatment for a patient. Such tests may include genetic or protein marker testing of tumor markers to determine susceptibility or resistance to a particular drug or class of drugs. For example, recently a mutation in von Hippel-Landau (VHL) gene have been found to be associated with a more favorable drug response for drugs such as SUTENT™, NEXAVAR™, and AVASTIN™. Other genetic and protein tests can be performed to link a treatment to an appropriate patient population.
The agents described above can be provided in formulations obtained from the manufacturer. Such formulations typically include the active components mixed with a pharmaceutically acceptable vehicle or excipient. The vehicle may contain minor amounts of auxiliary substances such as wetting or emulsifying agents. The formulations may also include ancillary substances, such as pharmacological agents, cytokines, or other biological response modifiers.
In other embodiments of the invention, the pharmaceutical composition comprising the agent is a sustained-release formulation, and/or a formulation that is administered using a sustained-release device. Such devices are well known in the art, and include, for example, transdermal patches, and miniature implantable pumps (such as described herein) that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to achieve a sustained-release effect with either a non-sustained-release or a sustained release pharmaceutical composition. For example, polypeptide agents and antibodies described herein are suitable agents for delivery using an osmotic delivery device such as the DUROS™ implantable device described above. In this embodiment, two or more such implantable delivery devices can be used, one including the GLP-1 receptor agonist and one or more including one or more additional beneficial agents, such as anticancer polypeptide formulations, antibodies, and the like. See, e.g., U.S. Patent Publication 2009/0202608, incorporated herein by reference in its entirety, for a description of the use of two or more implantable delivery devices.
The additional beneficial agents may also be formulated as particle and suspension formulations as described herein, if appropriate. Such particle and suspension formulations are useful with polypeptide agents and antibodies and can be delivered using implantable devices as described above. In addition to the suspension formulations, comprising a suspension vehicle and particle formulation, described above, some polypeptide agents (e.g., leuprolide acetate) can be directly dissolved or dispersed in a vehicle for delivery from implantable devices. For example, some polypeptides (e.g., leuprolide acetate) can be dissolved in non-aqueous polar aprotic solvents (e.g., dimethylsulfoxide) to provide peptide formulations (see, e.g., U.S. Pat. Nos. 5,932,547; 6,235,712; 5,981,489, incorporated herein by reference in their entireties). The use of one such formulation in an implantable osmotic delivery device is described below in Example 5. Other examples of peptide formulations include, but are not limited to, non-aqueous protic peptide formulations (see, e.g., U.S. Pat. No. 6,066,619, incorporated herein by reference in its entirety) and aqueous formulations of peptides (see, e.g., U.S. Pat. No. 6,068,850, incorporated herein by reference in its entirety).
Other suitable routes of administration for the beneficial agents include parenteral administration, such as subcutaneous (s.c.), intraperitoneal (i.p.), intramuscular (i.m.), intravenous (i.v.), or infusion, oral (p.o.) and pulmonary, nasal, topical, transdermal, and suppositories. Where the composition is administered via pulmonary delivery, the therapeutically effective dose is adjusted such that the soluble level of the agent in the bloodstream, is equivalent to that obtained with a therapeutically effective dose that is administered parenterally, for example s.c., i.p., i.m., or i.v. In some embodiments of the invention, the pharmaceutical composition comprising the beneficial agent is administered by i.m. or s.c. injection, particularly by i.m. or s.c. injection locally to the region where the GLP-1 receptor agonist is administered.
One or more therapeutically effective dose of the additional beneficial agent, such as an anticancer agent will be administered. By “therapeutically effective dose or amount” of each of these agents is intended an amount that when administered in combination with the other agents, brings about a positive therapeutic response with respect to treatment of an individual with cancer. Of particular interest is an amount of these agents that provides an anti-tumor effect, as defined herein. In certain embodiments, multiple therapeutically effective doses of the additional beneficial agent will be provided.
The additional beneficial agents can be administered prior to, concurrent with, or subsequent to administration of the GLP-1 receptor agonist. For example, initial treatment with a chemotherapeutic agent can be performed, followed by implantation of a delivery device including the GLP-1 receptor agonist formulation or vice versa. Moreover, the additional beneficial agent may be administered over the time that the GLP-1 receptor agonist formulation is also being delivered. By “concurrent therapy” is intended administration to a subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy.
The GLP-1 receptor agonists, e.g., exenatide and GLP-1(7-36)amide, optionally in combination with other beneficial agents, can be used to treat various cancers. In particular, as explained above, cancer cells are known to exhibit increased glycolysis as compared to normal cells. An advantage of the present invention is that inhibiting glucose availability to cancer cells by using a GLP-1 receptor agonist, such as exenatide and GLP-1(7-36)amide, effectively reduces the amount of energy metabolites such as ATP and NADH produced, thereby starving the cancer cell of energy.
Any number of cancers can benefit from the delivery of GLP-1 receptor agonists. For example, tumors or cancers such as hemangiomas, neufibromatosis, breast, colorectal, lung, brain and CNS, renal, gynecological (e.g., ovarian, fallopian, cervical, peritoneal), hematological (lymphoma, multiple myeloma, leukemia), neuroendocrine, mesothelioma, melanoma, prostate, esophagus, liver, gastric, rectal, carcinoid tumors; head and neck, squamous cell carcinoma, sarcomas, pancreas, colon, thymoma, thyroid, small intestine, bladder, testicular, bile duct, gall bladder, kidney, gastrointestinal stromal tumors, endometrial cancers and choriocarcinoma. A list of cancers that may benefit from delivery of the GLP-1 receptor agonists is shown in Table 2.
In some embodiments, the GLP-1 receptor agonists, are used in the treatment of hematological tumors and/or solid tumors. In a preferred embodiment, the GLP-1 receptor agonists, for example, exenatide and GLP-1(7-36)amide, are used in the treatment of solid tumors.
The GLP-1 receptor agonists are delivered in order to provide a positive therapeutic response. By “positive therapeutic response” it is intended the individual undergoing the combination treatment of a GLP-1 receptor agonist, such as exenatide and GLP-1(7-36)amide, and an additional beneficial agent exhibits an improvement in one or more symptoms of the cancer for which the individual is undergoing therapy. Therefore, for example, a positive therapeutic response refers to one or more of the following improvements in the disease: (1) reduction in tumor size; (2) reduction in the number of cancer cells; (3) inhibition (i.e., slowing to some extent, preferably halting) of tumor growth; (4) inhibition (i.e., slowing to some extent, preferably halting) of cancer cell infiltration into peripheral organs; (5) inhibition (i.e., slowing to some extent, preferably halting) of tumor metastasis; and (6) some extent of relief from one or more symptoms associated with the cancer. Such therapeutic responses may be further characterized as to degree of improvement. Thus, for example, an improvement may be characterized as a complete response. By “complete response” is documentation of the disappearance of all symptoms and signs of all measurable or evaluable disease confirmed by physical examination, laboratory, nuclear and radiographic studies (i.e., CT (computer tomography) and/or MRI (magnetic resonance imaging)), and other non-invasive procedures repeated for all initial abnormalities or sites positive at the time of entry into the study. Alternatively, an improvement in the disease may be categorized as stabilization of the disease or may be a partial response. By “partial response” is intended a reduction of greater than 50% in the sum of the products of the perpendicular diameters of one or more measurable lesions when compared with pretreatment measurements (for patients with evaluable response only, partial response does not apply).
In one embodiment, the GLP-1 receptor agonist is delivered in a suspension formulation, administered using an osmotic delivery device as described above. Examples of target rates of delivery for suspension formulations of the present invention, comprising GLP-1 receptor agonists, include, but are not limited to: suspension formulations comprising particle formulations comprising GLP-1 (e.g., GLP-1(7-36)amide), between about 20 μg/day and about 900 μg/day, preferably between about 100 μg/day and about 600 μg/day, for example, at about 480 μg/day; and suspension formulations comprising particle formulations comprising exenatide, between about 5 μg/day and about 320 μg/day, preferably between about 5 μg/day and about 160 μg/day, for example, at about 10 μg/day to about 20 μg/day, such as 10, 20, 40, 60, 80, 100, 120 μg/day, or any integers between the above ranges. An exit sheer rate of the suspension formulation from the osmotic delivery device is determined such that the target daily target delivery rate of the GLP-1 receptor agonist is reasonably achieved by substantially continuous, uniform delivery of the suspension formulation from the osmotic delivery device. Examples of exit sheer rates include, but are not limited to, about 1 to about 1.times.10.sup.4 reciprocal second, preferably about 4.times.10.sup.−2 to about 6.times.10.sup.4 reciprocal second, more preferably 5.times.10.sup.−3 to 1.times.10.sup.−3 reciprocal second.
As explained above, a subject being treated with the GLP-1 receptor agonist formulations of the present invention may also benefit from co-treatment with other beneficial agents, including anticancer agents described above, as well as antidiabetic agents.
Additional beneficial agents that can be delivered include, but are not limited to, pharmacologically beneficial peptides proteins, polypeptides, genes, gene products, other gene therapy agents, or other small molecules. The additional beneficial agents are useful for the treatment of a variety of conditions including but not limited to hemophilia and other blood disorders, growth disorders, diabetes, leukemia and lymphoma, hepatitis, renal failure, bacterial infection, viral infection (e.g., infection by HIV, HCV, etc.), hereditary diseases such as cerbrosidase deficiency and adenosine deaminase deficiency, hypertension, septic shock, autoimmune diseases (e.g., Graves disease, systemic lupus erythematosus and rheumatoid arthritis), shock and wasting disorders, cystic fibrosis, lactose intolerance, Crohn's disease, inflammatory bowel disease, Alzheimer's disease, metabolic disorders (such as obesity), and cancers.
The polypeptides may include but are not limited to the following: glucagon-like peptide 2 (GLP-2), cholecystokinin (CCK), CCK octapeptide, growth hormone, somatostatin; somatropin, somatotropin, somatotropin analogs, somatomedin-C, somatotropin plus an amino acid, somatotropin plus a protein; follicle stimulating hormone; luteinizing hormone, luteinizing hormone-releasing hormone (LHRH), LHRH analogs/agonists such as leuprolide, nafarelin and goserelin, LHRH antagonists; growth hormone releasing factor; calcitonin; colchicine; gonadotropins such as chorionic gonadotropin; antiandrogens such as flutamide, nilutamide and cytoprerone; aromatase inhibitors such as exemastane, letrozole and anastrazole; selective estrogen receptor modulators such as raloxifene, lasoxifene; oxytocin, octreotide; vasopressin; adrenocorticotrophic hormone; epidermal growth factor; fibroblast growth factor; platelet-derived growth factor; transforming growth factor; nerve growth factor; prolactin; cosyntropin; lypressin polypeptides such as thyrotropin releasing hormone; thyroid stimulation hormone; secretin; leptin; adiponectin; amylin, amylin analogs (e.g., pramlintide acetate); pancreozymin; enkephalin; glucagon; endocrine agents secreted internally and distributed by way of the bloodstream; carbohydrases, nucleases, lipase, proteases, amylase, or the like.
Further beneficial agents that may be delivered include but are not limited to the following: alpha antitrypsin; factor VII; factor IX, thrombin and other coagulation factors; insulin; peptide hormones; adrenal cortical stimulating hormone, thyroid stimulating hormone and other pituitary hormones; erythropoietin; growth factors such as granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, thrombopoietin, insulin-like growth factor 1; tissue plasminogen activator; CD4; 1-deamino-8-D-arginine vasopressin; interleukin-1 receptor antagonist; tumor necrosis factor, tumor necrosis factor receptor; tumor suppresser proteins; pancreatic enzymes; lactase; cytokines, including lymphokines, chemokines or interleukins such as interleukin-1, interleukin-2 and other members of the interleukin family (e.g., IL-1, 6, 12, 15, 17, 18, 32); cytotoxic proteins; superoxide dismutase; endocrine agents secreted internally and distributed in an animal by way of the bloodstream; recombinant antibodies, antibody fragments, humanized antibodies, single chain antibodies, monoclonal antibodies; avimers; or the like.
Further, the beneficial agents that may be administered include, but are not limited to, organic compounds including those compounds that transport across a vessel. Examples of beneficial agents that may be used in the practice of the present invention include, but are not limited to, the following: hypnotics and sedatives such as pentobarbital sodium, phenobarbital, secobarbital, thiopental, amides and ureas exemplified by diethylisovaleramide and alpha-bromo-isovaleryl urea, urethanes, or disulfanes; heterocyclic hypnotics such as dioxopiperidines, and glutarimides; antidepressants such as isocarboxazid, nialamide, phenelzine, imipramine, tranylcypromine, pargyline; tranquilizers such as chloropromazine, promazine, fluphenazine reserpine, deserpidine, meprobamate, benzodiazepines such as chlordiazepoxide; tricyclic antidepressants; anticonvulsants such as primidone, diphenylhydantoin, ethltoin, pheneturide, ethosuximide; muscle relaxants and anti-parkinson agents such as mephenesin, methocarbomal, trihexylphenidyl, biperiden, levo-dopa, also known as L-dopa and L-beta-3-4-dihydroxyphenylalanine; analgesics such as morphine, codeine, meperidine, nalorphine; antipyretics and anti-inflammatory agents such as aspirin, salicylamide, sodium salicylamide, naproxin, ibuprofen, acetaminophen; local anesthetics such as procaine, lidocaine, naepaine, piperocaine, tetracaine, dibucane; antispasmodics and antiulcer agents such as atropine, scopolamine, methscopolamine, oxyphenonium, papaverine, prostaglandins such as PGE1, PGE2, PGF1alpha, PGF2alpha, PGA; anti-microbials such as penicillin, tetracycline, oxytetracycline, chlorotetracycline, chloramphenicol, sulfonamides, bacitracin, chlorotetracycline, levofloxacin, erythromycin; anti-fungals such as Amphotericin B; anti-malarials such as 4-aminoquinolines, 8-aminoquinolines and pyrimethamine; hormonal agents such as prednisolone, cortisone, cortisol and triamcinolone, androgenic steroids (for example, methyltestosterone, fluoxmesterone), estrogenic steroids (for example, 17-beta-estradiol and ethinyl estradiol), progestational steroids (for example, 17-alpha-hydroxyprogesterone acetate, 19-nor-progesterone, norethindrone); sympathomimetic drugs such as epinephrine, amphetamine, ephedrine, norepinephrine; cardiovascular drugs such as procainamide, amyl nitrate, nitroglycerin, dipyridamole, sodium nitrate, mannitol nitrate; diuretics such as acetazolamide, chlorothiazide, flumethiazide; antiparasitic agents such as bephenium hydroxynaphthoate, dichlorophen, enitabas, dapsone; anti-neoplastic agents such as mechloroethamine, uracil mustard, 5-fluorouracil, 6-thioguanine, procarbazine, paclitaxel, docetaxel, carboplatin, gemcitabine, oxaliplatin, fludarabine, ara-C, camptothecin, bortezomib, methrotrexate, capecitabine, doxorubicin, vincristine, cyclophosphamide, etoposide; VEGF/EGF inhibitors (for example, small molecules and antibodies); VEGF/EGF receptor inhibitors; hypoglycemic drugs such as insulin related compounds (for example, isophane insulin suspension, protamine zinc insulin suspension, globin zinc insulin, extended insulin zinc suspension) tolbutamide, acetohexamide, tolazamide, chlorpropamide; nutritional agents such as vitamins, essential amino acids, and essential fats; eye drugs such as pilocarpine base, pilocarpine hydrochloride, pilocarpine nitrate; antiviral drugs such as disoproxil fumarate, aciclovir, cidofovir, docosanol, famciclovir, fomivirsen, foscarnet, ganciclovir, idoxuridine, penciclovir, trifluridine, tromantadine, valaciclovir, valganciclovir, vidarabine, amantadine, arbidol, oseltamivir, peramivir, rimantadine, zanamivir, abacavir, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine, zidovudine, tenofovir, efavirenz, delavirdine, nevirapine, loviride, amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir, enfuvirtide, adefovir, fomivirsen, imiquimod, inosine, podophyllotoxin, ribavirin, viramidine, fusion inhibitors specifically targeting viral surface proteins or viral receptors (for example, gp-41 inhibitor (T-20), CCR-5 inhibitor, enfuvirtide (FUZEON™)); anti-nausea (such as scopolamine, dimenhydrinate, granisetron, dolasetron, palonesetron, metaclopramide, ondansetron); iodoxuridine, hydrocortisone, eserine, phospholine, iodide, as well as other beneficial agents.
Numerous peptides, proteins, or polypeptides that are useful in the practice of the present invention are described herein. In addition to the peptides, proteins, or polypeptides described, modifications of these peptides, proteins, or polypeptides are also known to one of skill in the art and can be used in the practice of the present invention following the guidance presented herein. Such modifications include, but are not limited to, amino acid analogs, amino acid mimetics, analog polypeptides, or derivative polypeptides. Further, the beneficial agents disclosed herein may be formulated singly or in combination (e.g., mixtures).
Peptide YY (PYY) inhibits gut motility and blood flow (Laburthe, M., Trends Endocrinol Metab. 1(3):168-74 (1990), mediates intestinal secretion (Cox, H. M., et al., Br J Pharmacol 101(2):247-52 (1990); Playford, R. J., et al., Lancet 335(8705):1555-7 (1990)), stimulate net absorption (MacFayden, R. J., et al., Neuropeptides 7(3):219-27 (1986)), and two major in vivo variants (PYY and PYY3-36) have been identified (e.g., Eberlein, G. A., et al., Peptides 10 (4), 797-803 (1989)). The sequence of PYY, as well as analogs and derivatives thereof, including PYY3-36, are known in the art (e.g., U.S. Pat. Nos. 5,574,010 and 5,552,520). For ease of reference herein, the family of PYY polypeptides, PYY derivatives, variants and analogs are referred to collectively as PYY.
GIP is an insulinotropic peptide hormone (Efendic, S., Horm Metab Res. (2004) 36:742-746) and is secreted by the mucosa of the duodenum and jejunum in response to absorbed fat and carbohydrate that stimulate the pancreas to secrete insulin. GIP stimulates insulin secretion from pancreatic beta cells in the presence of glucose (Tseng et al., PATAS (1993) 90:1992-1996). GIP circulates as a biologically active 42-amino acid peptide. GIP is also known as glucose-dependent insulinotropic protein. The sequence of GIP, as well as peptide analogs and peptide derivatives thereof, are known in the art (see, e.g., Meier J. J., Diabetes Metab Res Rev. (2005) 21(2):91-117; Efendic S., Horm Metab Res. (2004) 36(11-12):742-746). For ease of reference herein, the family of GIP polypeptides, GIP derivatives, variants and analogs are referred to collectively as GIP.
Oxyntomodulin is a naturally occurring 37 amino acid peptide hormone found in the colon that has been found to suppress appetite and facilitate weight loss (Wynne K, et al., Int J Obes (Lond) 30(12):1729-36 (2006)). The sequence of oxyntomodulin, as well as analogs and derivatives thereof, are known in the art (e.g., U.S. Patent Publication Nos. 2005-0070469 and 2006-0094652). For ease of reference herein, the family of oxyntomodulin polypeptides, oxyntomodulin derivatives, variants and analogs are referred to collectively as oxyntomodulin.
Amylin, as well as analogs and derivatives thereof: are known in the art (e.g., U.S. Pat. Nos. 5,686,411, 5,814,600, 5,998,367, 6,114,304, 6,410,511, 6,608,029, and 6,610,824). For ease of reference herein, the family of amylin polypeptides, amylin derivatives, variants and analogs are referred to collectively as amylin.
The cDNA sequence encoding the human leptin protein hormone is known (e.g., Masuzaki, H., et al. (Diabetes 44: 855-858, 1995)). Leptin, as well as analogs and derivatives thereof, are known in the art (e.g., U.S. Pat. Nos. 5,521,283, 5,525,705, 5,532,336, 5,552,522, 5,552,523, 5,552,524, 5,554,727, 5,559,208, 5,563,243, 5,563,244, 5,563,245, 5,567,678, 5,567,803, 5,569,743, 5,569,744, 5,574,133, 5,580,954, 5,594,101, 5,594,104, 5,605,886, 5,691,309, and 5,719,266; P.C.T. International Patent Publication Nos. WO96/22308, WO96/31526, WO96/34885, 97/46585, WO97/16550, and WO 97/20933; European Patent Publication No. EP 0 741 187). For ease of reference herein, the family of leptin polypeptides, leptin derivatives, variants and analogs are referred to collectively as leptin.
Further, oligonucleotides (e.g., RNA, DNA, alternative backbones) may be used as beneficial agents in the practice of the present invention. In one embodiment therapeutic RNA molecules may include, but are not limited to, small nuclear RNAs (snRNAs), and small interfering RNA strands (siRNA) for use in RNA interference (RNAi) inhibition of gene expression. RNAi inhibition typically occurs at the stage of translation or by hindering the transcription of specific genes. RNAi targets include, but are not limited to, RNA from viruses and genes with roles in regulating development and genome maintenance.
The beneficial agents can also be in various forms including, but not limited to, the following: uncharged molecules; components of molecular complexes; and pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate, laurates, palmatates, phosphate, nitrate, borate, acetate, maleate, tartrate, oleates, or salicylates. For acidic drugs, salts of metals, amines or organic cations, for example, quaternary ammonium, can be employed. Furthermore, simple derivatives of the drug such as esters, ethers, amides and the like that have solubility characteristics suitable for the purpose of the invention can also be used herein. The formulation used can have been in various art known forms such as solution, dispersion, paste, cream, particle, granule, tablet, emulsions, suspensions, powders and the like. In addition to the one or more beneficial agents, the beneficial agent formulation may optionally include pharmaceutically acceptable carriers and/or additional ingredients such as antioxidants, stabilizing agents, buffers, and permeation enhancers.
The amount of beneficial agent used is that amount necessary to deliver a therapeutically effective amount of the agent to achieve the desired therapeutic result. In practice, this will vary depending upon such variables, for example, as the particular agent, the site of delivery, the severity of the condition, and the desired therapeutic effect. Beneficial agents and their dosage unit amounts are known to the prior art in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Ed., (2005), McGraw Hill; Remington's Pharmaceutical Sciences, 18th Ed., (1995), Mack Publishing Co.; and Martin's Physical Pharmacy and Pharmaceutical Sciences, 1.00 edition (2005), Lippincott Williams & Wilkins.
The additional beneficial agent can be delivered using any of the various delivery techniques outlined above, including without limitation parenterally (including by subcutaneous, intravenous, intramedullary, intraarticular, intramuscular, or intraperitoneal injection) rectally, topically, transdermally, intranasally, by inhalation, or orally (for example, in capsules, suspensions, or tablets). In certain embodiments, the agent is in a sustained-release formulation, or administered using a sustained-release device. Such devices are well known in the art, and include, for example, transdermal patches, and miniature implantable pumps (such as the DUROS™ delivery device described herein) that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to achieve a sustained-release effect with a non-sustained-release pharmaceutical composition. If an osmotic delivery device is used, the volume of a beneficial agent chamber comprising the beneficial agent formulation is between about 50 μl to about 1000 μl, more preferably between about 100 μl and about 500 μl, more preferably between about 150 μl and about 200 μl. Moreover, two or more such devices can be used, one including the GLP-1 receptor agonist and one or more including one or more additional beneficial agents, such as an antidiabetic compound. See, e.g., U.S. Patent Publication 2009/0202608, incorporated herein by reference in its entirety, for a description of the use of two or more implantable delivery devices.
An example of a cancer treatment using delivery of an anticancer agent from a first osmotic delivery device and delivery of a GLP-1 receptor agonist from a second osmotic delivery device is presented below in Example 5. In the example, the cancer is prostate cancer, the anticancer agent is leuprolide acetate and the GLP-1 receptor agonist is exenatide.
Other objects may be apparent to one of ordinary skill upon reviewing the following specification and claims.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the devices, methods, and formulae of the present invention, and are not intended to limit the scope of what the inventor regards as the invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
The compositions produced according to the present invention meet the specifications for content and purity required of pharmaceutical products.
This example describes making exenatide particle formulations.
A. Formulation 1
Exenatide (0.25 g) was dissolved in 50 mM sodium citrate buffer at pH 6.04. The solution was dialyzed with a formulation solution containing sodium citrate buffer, sucrose, and methionine. The formulated solution was then spray dried using Buchi 290 with 0.7 mm nozzle, outlet temperature of 75° C., atomization pressure of 100 Psi, solid content of 2%, and flow rate of 2.8 mL/min. The dry powder contained 21.5% of exenatide with 4.7% residual moisture and 0.228 g/ml density.
B. Formulations 2 and 3
Two additional formulations of exenatide were prepared essentially by the method just described. Following here in Table 3 is a summary of the weight percentages (wt %) of the components of the Formulations 1, 2 and 3.
This example describes making a GLP-1(7-36)amide particle formulation. GLP-1(7-36)amide (1.5 g) was dissolved in 5 mM sodium citrate buffer at pH 4. The solution was dialyzed with a formulation solution containing sodium citrate buffer and methionine. The formulated solution was then spray dried using Buchi 290 with 0.7 mm nozzle, outlet temperature of 70° C., atomization pressure of 100 Psi, solid content of 1.5%, and flow rate of 5 mL/min. The dry powder contained 90% of GLP-1(7-36)amide.
This example describes making suspension formulations comprising a suspension vehicle and an exenatide particle formulation.
A. Suspension Formulation of 20 wt % Exenatide Particles
An exenatide particle formulation was generated by spray-drying, and contained 20 wt % exenatide, 32 wt % sucrose, 16 wt % methionine and 32 wt % citrate buffer.
A suspension vehicle was formed by dissolving the polymer polyvinylpyrrolidone in the solvent benzyl benzoate at approximately a 50/50 ratio by weight. The vehicle viscosity was approximately 12,000 to 18,000 poise when measured at 33° C. Particles containing the peptide exenatide were dispersed throughout the vehicle at a concentration of 10% particles by weight.
B. Suspension Formulations of Particle Formulations 1, 2, and 3
A suspension vehicle was formed by dissolving the polymer polyvinylpyrrolidone K-17 (typically having an approximate average molecular weight range of 7,900-10,800) in the solvent benzyl benzoate heated to approximately 65° C. under a dry atmosphere and reduced pressure at approximately a 50/50 ratio by weight. The vehicle viscosity was approximately 12,000 to 18,000 poise when measured at 33° C. Particle formulations 1-3, described in Example 1, were dispersed throughout the vehicle at the concentrations (by weight percent) shown in Table 4.
This example describes making a suspension formulation comprising a suspension vehicle and an GLP-1(7-36)amide particle formulation. A GLP-1(7-36)amide particle formulation was generated by spray-drying, and contained 90 wt % GLP-1, 5 wt % methionine and 5 wt % citrate buffer.
A suspension vehicle containing the polymer polyvinylpyrrolidone was dissolved in the solvent benzyl benzoate at approximately a 50/50 ratio by weight. The vehicle viscosity was approximately 12,000 to 18,000 poise when measured at 33° C. Particles containing the peptide GLP-1(7-36)amide were dispersed throughout the vehicle at a concentration of 33% particles by weight.
Leuprolide acetate, an LHRH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Animal and human studies indicate that following an initial stimulation, chronic administration of leuprolide acetate results in suppression of testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormone-dependent tumors (prostatic tumors in Noble and Dunning male rats and DMBA-induced mammary tumors in female rats) as well as atrophy of the reproductive organs. In humans, administration of leuprolide acetate results in an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males). However, continuous administration of leuprolide acetate results in decreased level of LH and FSH. In males, testosterone is reduced to castrate levels. These decreases occur within two to six weeks after initiation of treatment, and castrate levels of testosterone in prostatic cancer patients have been demonstrated for multiyear periods. Leuprolide acetate is not active when given orally.
An implantable device containing leuprolide acetate for the treatment of prostate cancer is assembled as described in U.S. Pat. No. 5,728,396, incorporated herein by reference in its entirety. The device includes the following components:
Reservoir (Titanium, Ti6A 14V alloy) (4 mm outside diameter, 3 mm inside diameter)
Piston (C-Flex™)
Lubricant (silicone medical fluid) Compressed osmotic engine (76.4% NaCl, 15.5% sodium carboxymethyl cellulose, 6% povidone, 0.5% Mg Stearate, 1.6% water) PEG 400 (8 mg added to osmotic engine to fill air spaces) Membrane plug (polyurethane polymer, injection molded to desired shape) Back diffusion Regulating Outlet (polyethylene) Drug formulation (1) 0.150 g of 60% water and 40% leuprolide acetate; or (2) leuprolide acetate dissolved in DMSO to a measured content of 65 mg leuprolide.
To assemble the device, the piston and inner diameter of the reservoir are lightly lubricated. The piston is inserted about 0.5 cm into the reservoir at the membrane end. PEG 400 is added into the reservoir. Two osmotic engine tablets (40 mg each) are then inserted into the reservoir from the membrane end. After insertion, the osmotic engine is flush with the end of the reservoir. The membrane plug is inserted by lining up the plug with the reservoir and pushing gently until the retaining features of the plug are fully engaged in the reservoir. Formulation is loaded into a syringe which is then used to fill the reservoir from the outlet end by injecting formulation into the open tube until the formulation is about 3 mm from the end. The filled reservoir is centrifuged (outlet end “up”) to remove any air bubbles that have been trapped in the formulation during filling. The outlet is screwed into the open end of the reservoir until completely engaged. As the outlet is screwed in, excess formulation exits out of the orifice ensuring a uniform fill.
These devices deliver about 0.35 μL/day leuprolide formulation containing on average 150 μg leuprolide in the amount delivered per day. They provide delivery of leuprolide at this rate for at least one year. The devices can achieve approximately 70% steady-state delivery by day 14.
Exenatide suspension formulations are produced as described in Example 1 and loaded into an implantable delivery device as above. Two implantable devices, one including an exenatide formulation and one including a leuprolide formulation are implanted under local anesthetic and by means of an incision in a patient suffering from advanced prostatic cancer. Implantation can be accomplished using, for example, an implanter device. See e.g., U.S. Pat. No. 6,190,350, incorporated herein by reference in its entirety. After an appropriate period of time, the implantable delivery devices are removed under local anesthetic. New devices may be inserted at that time.
Embodiments of the present invention include, but are not limited to, the following:
1. A method of treating cancer in a subject in need of such treatment, comprising: administering a GLP-1 receptor agonist to said subject.
2. The method of embodiment 1, wherein the GLP-1 receptor agonist is a small molecule.
3. The method of embodiment 1, wherein the GLP-1 receptor agonist is a peptide, polypeptide or protein.
4. The method of embodiment 3, wherein the GLP-1 receptor agonist is a glucagon-like peptide-1 (GLP-1), a derivative of GLP-1, or an analog of GLP-1.
5. The method of embodiment 4, wherein the GLP-1 receptor agonist is GLP(7-36)amide comprising the sequence of SEQ ID NO: 1.
6. The method of embodiment 3, wherein the GLP-1 receptor agonist is exenatide, a derivative of exenatide, or an analog of exenatide.
7. The method of embodiment 6, wherein the GLP-1 receptor agonist is synthetic exenatide peptide comprising the sequence of SEQ ID NO:2.
8. The method of embodiment 4, wherein the GLP-1 receptor agonist is selected from the group consisting of liraglutide, albiglutide, semaglutide and taspoglutide.
9. The method of embodiment 6, wherein the GLP-1 receptor agonist is lixisenatide.
10. The method of any one of embodiments 1-9, wherein the GLP-1 receptor agonist is provided in a suspension formulation comprising: (a) a particle formulation comprising said GLP-1 receptor agonist; and (b) a vehicle formulation, wherein the particle formulation is dispersed in the vehicle.
11. The method of embodiment 10, wherein (a) the particle formulation additionally comprises a disaccharide, methionine and a buffer and (b) the vehicle formulation is a non-aqueous, single-phase suspension vehicle comprising one or more pyrrolidone polymers and one or more solvents selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof; wherein the suspension vehicle exhibits viscous fluid characteristics, and the particle formulation is dispersed in the vehicle.
12. The method of embodiment 11, wherein the buffer is selected from the group consisting of citrate, histidine, succinate, and mixtures thereof.
13. The method of embodiment 12, wherein the buffer is citrate.
14. The method of embodiment 11, wherein the disaccharide is selected from the group consisting of lactose, sucrose, trehalose, cellobiose, and mixtures thereof.
15. The method of embodiment 11, wherein the particle formulation is a spray dried preparation of particles.
16. The method of embodiment 11, wherein the solvent is selected from the group consisting of lauryl lactate, benzyl benzoate, and mixtures thereof.
17. The method of embodiment 16, wherein the solvent consists essentially of benzyl benzoate.
18. The method of embodiment 11, wherein the pyrrolidone polymer consists essentially of polyvinylpyrrolidone.
19. The method of embodiment 11, wherein the vehicle consists essentially of a pyrrolidone polymer and benzyl benzoate.
20. The method of embodiment 19, wherein the vehicle is about 50% solvent and about 50% polymer.
21. The method of embodiment 11, wherein the suspension formulation has an overall moisture content of less than or equal to about 10 wt %.
22. The method of any one of embodiments 1-21, wherein the GLP-1 receptor agonist is delivered using an implantable osmotic delivery device.
23. The method of embodiment 22, wherein the osmotic delivery device provides continuous delivery of the GLP-1 receptor agonist for a period of at least one month.
24. The method of any one of embodiments 1-9, wherein the GLP-1 receptor agonist is provided in an injectable formulation.
25. The method of any one of embodiments 1-24, wherein a beneficial agent in addition to the GLP-1 receptor agonist is delivered to said subject.
26. The method of embodiment 25, wherein the additional beneficial agent is an anticancer agent.
27. The method of embodiment 26, wherein the anticancer agent is a chemotherapeutic agent.
28. The method of embodiment 26, wherein the anticancer agent is an anticancer antibody.
29. The method of any one of embodiments 25-28, wherein the additional beneficial agent is an antidiabetic agent.
30. The method of any one of embodiments 25-29, wherein the additional beneficial agent is delivered using an implantable osmotic delivery device.
31. The method of embodiment 30, wherein the osmotic delivery device provides continuous delivery of the GLP-1 receptor agonist for a period of at least one month.
32. The method of either one of embodiments 30 or 31, wherein the additional beneficial agent is a luteinizing hormone-releasing hormone (LHRH) agonist.
33. The method of any one of embodiments 25-29, wherein the additional beneficial agent is provided in an injectable formulation.
34. The method of any one of embodiments 25-29, wherein the additional beneficial agent is provided in an oral formulation.
35. The method of embodiment 25, wherein the additional beneficial agent is GIP.
36. The method of any one of embodiments 25-35, wherein the additional beneficial agent is delivered prior to the GLP-1 receptor agonist.
37. The method of any one of embodiments 25-35, wherein the additional beneficial agent is delivered subsequent to the GLP-1 receptor agonist.
38. The method of any one of embodiments 25-35, wherein the additional beneficial agent is delivered concurrent with the GLP-1 receptor agonist.
As is apparent to one of skill in the art, various modification and variations of the above embodiments can be made without departing from the spirit and scope of this invention. Such modifications and variations are within the scope of this invention.
This application is a continuation of U.S. patent application Ser. No. 14/525,201, filed on Oct. 27, 2014, which is a continuation of U.S. patent application Ser. No. 13/372,326, filed Feb. 13, 2012, now abandoned, which claims the benefit of U.S. Provisional Application No. 61/443,628, filed Feb. 16, 2011. The contents of the aforementioned patent applications are herein incorporated by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2110208 | Eggert | Mar 1938 | A |
| 2168437 | Buercklin | Aug 1939 | A |
| 2531724 | Cevasco | Nov 1950 | A |
| D179537 | Floyd et al. | Jan 1957 | S |
| 3025991 | Gillon | Mar 1962 | A |
| 3122162 | Sands | Feb 1964 | A |
| 3523906 | Vrancken et al. | Aug 1970 | A |
| 3625214 | Higuchi | Dec 1971 | A |
| 3632768 | Bergy et al. | Jan 1972 | A |
| 3691090 | Kitajima et al. | Sep 1972 | A |
| D226915 | Huggins | May 1973 | S |
| 3732865 | Higuchi et al. | May 1973 | A |
| 3737337 | Schnoring et al. | Jun 1973 | A |
| 3773919 | Boswell et al. | Nov 1973 | A |
| 3797492 | Place | Mar 1974 | A |
| 3869549 | Geller | Mar 1975 | A |
| 3891570 | Fukushima et al. | Jun 1975 | A |
| D236035 | Ciencewicki | Jul 1975 | S |
| 3960757 | Morishita et al. | Jun 1976 | A |
| 3987790 | Eckenhoff et al. | Oct 1976 | A |
| 3995631 | Higuchi et al. | Dec 1976 | A |
| 3995632 | Nakano et al. | Dec 1976 | A |
| 4008719 | Theeuwes et al. | Feb 1977 | A |
| 4034756 | Higuchi et al. | Jul 1977 | A |
| 4078060 | Benson et al. | Mar 1978 | A |
| 4111201 | Theeuwes | Sep 1978 | A |
| 4111202 | Theeuwes | Sep 1978 | A |
| 4111203 | Theeuwes | Sep 1978 | A |
| 4203439 | Theeuwes | May 1980 | A |
| 4211771 | Witkowski et al. | Jul 1980 | A |
| 4221862 | Naito et al. | Sep 1980 | A |
| 4243030 | Lynch et al. | Jan 1981 | A |
| D258837 | Spranger et al. | Apr 1981 | S |
| D259458 | Fuller et al. | Jun 1981 | S |
| 4305927 | Theeuwes et al. | Dec 1981 | A |
| 4310516 | Chang et al. | Jan 1982 | A |
| 4340054 | Michaels | Jul 1982 | A |
| 4350271 | Eckenhoff | Sep 1982 | A |
| 4373527 | Fischell | Feb 1983 | A |
| 4376118 | Daher et al. | Mar 1983 | A |
| 4384975 | Fong | May 1983 | A |
| 4389330 | Tice et al. | Jun 1983 | A |
| 4439196 | Higuchi | Mar 1984 | A |
| 4444498 | Heinemann | Apr 1984 | A |
| 4455143 | Theeuwes et al. | Jun 1984 | A |
| 4455145 | Theeuwes | Jun 1984 | A |
| 4530840 | Tice et al. | Jul 1985 | A |
| 4552561 | Eckenhoff et al. | Nov 1985 | A |
| 4588614 | Lauchenauer | May 1986 | A |
| 4594108 | Greminger, Jr. et al. | Jun 1986 | A |
| 4609374 | Ayer | Sep 1986 | A |
| 4639244 | Rizk et al. | Jan 1987 | A |
| 4655462 | Balsells | Apr 1987 | A |
| 4673405 | Guittard et al. | Jun 1987 | A |
| 4675184 | Hasegawa et al. | Jun 1987 | A |
| 4695623 | Stabinsky | Sep 1987 | A |
| 4727138 | Goeddel et al. | Feb 1988 | A |
| 4734284 | Terada et al. | Mar 1988 | A |
| 4737437 | Gutsell, Jr. et al. | Apr 1988 | A |
| 4743449 | Yoshida et al. | May 1988 | A |
| 4753651 | Eckenhoff | Jun 1988 | A |
| 4762791 | Goeddel et al. | Aug 1988 | A |
| 4765989 | Wong et al. | Aug 1988 | A |
| 4783337 | Wong et al. | Nov 1988 | A |
| 4818517 | Kwee et al. | Apr 1989 | A |
| 4820638 | Swetly et al. | Apr 1989 | A |
| 4826144 | Balsells | May 1989 | A |
| 4830344 | Balsells | May 1989 | A |
| 4840896 | Reddy et al. | Jun 1989 | A |
| 4845196 | Cowling | Jul 1989 | A |
| 4847079 | Kwan | Jul 1989 | A |
| 4851228 | Zentner et al. | Jul 1989 | A |
| 4865845 | Eckenhoff et al. | Sep 1989 | A |
| 4873080 | Brickl et al. | Oct 1989 | A |
| 4874388 | Wong et al. | Oct 1989 | A |
| 4876781 | Balsells | Oct 1989 | A |
| 4885166 | Meyer et al. | Dec 1989 | A |
| 4886668 | Haslam et al. | Dec 1989 | A |
| 4892778 | Theeuwes et al. | Jan 1990 | A |
| 4893795 | Balsells | Jan 1990 | A |
| 4897471 | Stabinsky | Jan 1990 | A |
| 4907788 | Balsells | Mar 1990 | A |
| 4915366 | Balsells | Apr 1990 | A |
| 4915949 | Wong et al. | Apr 1990 | A |
| 4915954 | Ayer et al. | Apr 1990 | A |
| 4917887 | Hauptmann et al. | Apr 1990 | A |
| 4917895 | Lee et al. | Apr 1990 | A |
| 4923805 | Reddy et al. | May 1990 | A |
| 4927687 | Nuwayser | May 1990 | A |
| 4929554 | Goeddel et al. | May 1990 | A |
| 4931285 | Edgren et al. | Jun 1990 | A |
| 4934666 | Balsells | Jun 1990 | A |
| 4940465 | Theeuwes et al. | Jul 1990 | A |
| 4940588 | Sparks et al. | Jul 1990 | A |
| 4952402 | Sparks et al. | Aug 1990 | A |
| 4957119 | de Nijs | Sep 1990 | A |
| 4961253 | Balsells | Oct 1990 | A |
| 4964204 | Balsells | Oct 1990 | A |
| 4969884 | Yum | Nov 1990 | A |
| 4974821 | Balsells | Dec 1990 | A |
| 4976966 | Theeuwes et al. | Dec 1990 | A |
| 5004689 | Fiers et al. | Apr 1991 | A |
| 5006346 | Theeuwes et al. | Apr 1991 | A |
| 5019382 | Cummins, Jr. | May 1991 | A |
| 5019400 | Gombotz et al. | May 1991 | A |
| 5023088 | Wong et al. | Jun 1991 | A |
| 5024842 | Edgren et al. | Jun 1991 | A |
| 5030216 | Theeuwes et al. | Jul 1991 | A |
| 5034229 | Magruder et al. | Jul 1991 | A |
| 5057318 | Magruder et al. | Oct 1991 | A |
| 5059423 | Magruder et al. | Oct 1991 | A |
| 5066436 | Komen et al. | Nov 1991 | A |
| 5071642 | Lahr et al. | Dec 1991 | A |
| 5072070 | Balsells | Dec 1991 | A |
| 5079388 | Balsells | Jan 1992 | A |
| 5091188 | Haynes | Feb 1992 | A |
| 5108078 | Balsells | Apr 1992 | A |
| 5110596 | Magruder et al. | May 1992 | A |
| 5112614 | Magruder et al. | May 1992 | A |
| 5113938 | Clayton | May 1992 | A |
| 5117066 | Balsells | May 1992 | A |
| D326718 | Maxwell | Jun 1992 | S |
| 5118666 | Habener | Jun 1992 | A |
| 5120306 | Gosselin | Jun 1992 | A |
| 5120712 | Habener | Jun 1992 | A |
| 5120832 | Goeddel et al. | Jun 1992 | A |
| 5122128 | Cardinal et al. | Jun 1992 | A |
| 5122377 | Miller | Jun 1992 | A |
| 5126142 | Ayer et al. | Jun 1992 | A |
| 5126147 | Silvestri et al. | Jun 1992 | A |
| 5134244 | Balsells | Jul 1992 | A |
| 5137727 | Eckenhoff | Aug 1992 | A |
| D329278 | Gallup | Sep 1992 | S |
| 5151093 | Theeuwes et al. | Sep 1992 | A |
| 5160122 | Balsells | Nov 1992 | A |
| 5160743 | Edgren et al. | Nov 1992 | A |
| 5161806 | Balsells | Nov 1992 | A |
| 5180591 | Margruder et al. | Jan 1993 | A |
| 5190765 | Jao et al. | Mar 1993 | A |
| 5203849 | Balsells | Apr 1993 | A |
| 5204108 | Illum | Apr 1993 | A |
| 5207752 | Sorensen et al. | May 1993 | A |
| 5209746 | Balaban et al. | May 1993 | A |
| 5213809 | Wright et al. | May 1993 | A |
| 5213810 | Steber | May 1993 | A |
| 5219572 | Sivaramakrishnan | Jun 1993 | A |
| 5221278 | Linkwitz et al. | Jun 1993 | A |
| 5223265 | Wong | Jun 1993 | A |
| 5225205 | Orsolini | Jul 1993 | A |
| 5231176 | Goeddel et al. | Jul 1993 | A |
| 5234424 | Yum et al. | Aug 1993 | A |
| 5234692 | Magruder et al. | Aug 1993 | A |
| 5234693 | Magruder et al. | Aug 1993 | A |
| 5234695 | Hobbs et al. | Aug 1993 | A |
| 5252338 | Jao et al. | Oct 1993 | A |
| 5260069 | Chen | Nov 1993 | A |
| D342855 | Butler, II | Jan 1994 | S |
| 5278151 | Korb et al. | Jan 1994 | A |
| 5279608 | Cherif Cheikh | Jan 1994 | A |
| 5284655 | Bogdansky et al. | Feb 1994 | A |
| 5288501 | Nürnberg et al. | Feb 1994 | A |
| 5288502 | Mcginity et al. | Feb 1994 | A |
| 5290271 | Jernberg | Mar 1994 | A |
| 5300079 | Niezink et al. | Apr 1994 | A |
| 5300302 | Tachon et al. | Apr 1994 | A |
| 5308348 | Balaban et al. | May 1994 | A |
| 5312335 | McKinnon et al. | May 1994 | A |
| 5312389 | Theeuwes et al. | May 1994 | A |
| 5312390 | Wong | May 1994 | A |
| 5318558 | Linkwitz et al. | Jun 1994 | A |
| 5318780 | Viegas et al. | Jun 1994 | A |
| 5320616 | Magndu et al. | Jun 1994 | A |
| 5324280 | Wong et al. | Jun 1994 | A |
| 5336057 | Fukuda et al. | Aug 1994 | A |
| 5336505 | Ng et al. | Aug 1994 | A |
| 5352662 | Brooks et al. | Oct 1994 | A |
| 5368588 | Bettinger | Nov 1994 | A |
| 5368863 | Eckenhoff et al. | Nov 1994 | A |
| 5371089 | Rattan | Dec 1994 | A |
| 5374620 | Clark et al. | Dec 1994 | A |
| 5385738 | Yamahira et al. | Jan 1995 | A |
| 5385887 | Yim et al. | Jan 1995 | A |
| 5407609 | Tice et al. | Apr 1995 | A |
| D358644 | Park | May 1995 | S |
| 5411951 | Mitchell | May 1995 | A |
| 5413572 | Wong et al. | May 1995 | A |
| 5413672 | Hirotsuji et al. | May 1995 | A |
| 5424286 | Eng | Jun 1995 | A |
| 5428024 | Chu et al. | Jun 1995 | A |
| 5429602 | Hauser | Jul 1995 | A |
| 5439688 | Orsolini et al. | Aug 1995 | A |
| 5443459 | Wong et al. | Aug 1995 | A |
| 5445829 | Paradissis et al. | Aug 1995 | A |
| 5456679 | Balaban et al. | Oct 1995 | A |
| 5458888 | Chen | Oct 1995 | A |
| 5464929 | Bezwada et al. | Nov 1995 | A |
| 5472708 | Chen | Dec 1995 | A |
| 5478564 | Wantier et al. | Dec 1995 | A |
| 5486365 | Takado et al. | Jan 1996 | A |
| 5498255 | Wong et al. | Mar 1996 | A |
| 5511355 | Dingler | Apr 1996 | A |
| 5512293 | Landrau et al. | Apr 1996 | A |
| 5512549 | Chen et al. | Apr 1996 | A |
| 5514110 | Teh | May 1996 | A |
| 5529914 | Hubbell et al. | Jun 1996 | A |
| 5531736 | Wong et al. | Jul 1996 | A |
| 5540665 | Mercado et al. | Jul 1996 | A |
| 5540912 | Roorda et al. | Jul 1996 | A |
| 5541172 | Labrie et al. | Jul 1996 | A |
| 5542682 | Goldstein et al. | Aug 1996 | A |
| 5543156 | Roorda et al. | Aug 1996 | A |
| 5545618 | Buckley et al. | Aug 1996 | A |
| 5556642 | Kobayashi et al. | Sep 1996 | A |
| 5557318 | Gabriel | Sep 1996 | A |
| 5571525 | Roorda et al. | Nov 1996 | A |
| 5574008 | Johnson et al. | Nov 1996 | A |
| 5574137 | Gray et al. | Nov 1996 | A |
| 5580578 | Oshlack et al. | Dec 1996 | A |
| 5589167 | Cleland et al. | Dec 1996 | A |
| 5595751 | Bezwada | Jan 1997 | A |
| 5595759 | Wright et al. | Jan 1997 | A |
| 5597579 | Bezwada et al. | Jan 1997 | A |
| 5602010 | Hauptmann et al. | Feb 1997 | A |
| 5605688 | Himmler et al. | Feb 1997 | A |
| 5607687 | Bezwada et al. | Mar 1997 | A |
| 5609885 | Rivera et al. | Mar 1997 | A |
| 5614221 | Fjellstrom | Mar 1997 | A |
| 5614492 | Habener | Mar 1997 | A |
| 5618552 | Bezwada et al. | Apr 1997 | A |
| 5620698 | Bezwada et al. | Apr 1997 | A |
| 5620705 | Dong et al. | Apr 1997 | A |
| 5630796 | Bellhouse et al. | May 1997 | A |
| 5633011 | Dong et al. | May 1997 | A |
| 5635213 | Nystrom et al. | Jun 1997 | A |
| 5639477 | Maruyama et al. | Jun 1997 | A |
| 5639640 | Reddy et al. | Jun 1997 | A |
| 5645850 | Bezwada et al. | Jul 1997 | A |
| 5648088 | Bezwada et al. | Jul 1997 | A |
| 5650173 | Ramstack et al. | Jul 1997 | A |
| 5654008 | Herbert et al. | Aug 1997 | A |
| 5654010 | Johnson et al. | Aug 1997 | A |
| 5656297 | Bernstein et al. | Aug 1997 | A |
| 5656299 | Kino et al. | Aug 1997 | A |
| 5658593 | Orly et al. | Aug 1997 | A |
| 5660847 | Magruder et al. | Aug 1997 | A |
| 5660858 | Parikh et al. | Aug 1997 | A |
| 5660861 | Jao et al. | Aug 1997 | A |
| 5667808 | Johnson et al. | Sep 1997 | A |
| 5668170 | Gyory | Sep 1997 | A |
| 5672549 | Minami et al. | Sep 1997 | A |
| 5676942 | Testa et al. | Oct 1997 | A |
| 5686097 | Taskovich et al. | Nov 1997 | A |
| 5688801 | Mesens et al. | Nov 1997 | A |
| 5690925 | Gray et al. | Nov 1997 | A |
| 5690952 | Magruder et al. | Nov 1997 | A |
| 5697113 | Shatz et al. | Dec 1997 | A |
| 5698213 | Jamiolkowski et al. | Dec 1997 | A |
| 5700486 | Canal et al. | Dec 1997 | A |
| 5700583 | Jamiolkowski et al. | Dec 1997 | A |
| 5703200 | Bezwada et al. | Dec 1997 | A |
| 5707644 | Illum | Jan 1998 | A |
| 5711967 | Juch | Jan 1998 | A |
| 5713847 | Howard, III et al. | Feb 1998 | A |
| 5718922 | Herrero-Vanrell | Feb 1998 | A |
| 5728088 | Margruder et al. | Mar 1998 | A |
| 5728396 | Peery et al. | Mar 1998 | A |
| 5733572 | Unger et al. | Mar 1998 | A |
| 5736159 | Chen et al. | Apr 1998 | A |
| 5738845 | Imakawa | Apr 1998 | A |
| 5747058 | Tipton et al. | May 1998 | A |
| 5756450 | Lorenz et al. | May 1998 | A |
| 5767251 | Reddy et al. | Jun 1998 | A |
| 5770231 | Mesens et al. | Jun 1998 | A |
| 5782396 | Mastri et al. | Jul 1998 | A |
| 5792477 | Rickey et al. | Aug 1998 | A |
| 5795591 | Lee et al. | Aug 1998 | A |
| 5795779 | McCormick et al. | Aug 1998 | A |
| 5807876 | Armistead et al. | Sep 1998 | A |
| 5814323 | Lyle | Sep 1998 | A |
| D399821 | Tyneski et al. | Oct 1998 | S |
| 5817129 | Labrecque et al. | Oct 1998 | A |
| 5830501 | Dong et al. | Nov 1998 | A |
| 5836935 | Ashton et al. | Nov 1998 | A |
| 5843891 | Sherman | Dec 1998 | A |
| 5844017 | Jamiolkowski et al. | Dec 1998 | A |
| 5851451 | Takechi et al. | Dec 1998 | A |
| 5858746 | Hubbell et al. | Jan 1999 | A |
| 5859150 | Jamiolkowski et al. | Jan 1999 | A |
| 5861166 | Eckenhoff | Jan 1999 | A |
| 5871770 | Margruder et al. | Feb 1999 | A |
| 5871778 | Kino et al. | Feb 1999 | A |
| 5874388 | Hsu | Feb 1999 | A |
| 5876746 | Jona et al. | Mar 1999 | A |
| 5882676 | Lee et al. | Mar 1999 | A |
| D408917 | Hacker | Apr 1999 | S |
| 5904935 | Eckenhoff et al. | May 1999 | A |
| 5906816 | Soos et al. | May 1999 | A |
| 5906830 | Farinas et al. | May 1999 | A |
| 5908621 | Glue et al. | Jun 1999 | A |
| 5916598 | Rickey et al. | Jun 1999 | A |
| 5922253 | Herbert et al. | Jul 1999 | A |
| 5928666 | Farinas et al. | Jul 1999 | A |
| 5932547 | Stevenson et al. | Aug 1999 | A |
| 5938654 | Wong et al. | Aug 1999 | A |
| 5939286 | Johnson et al. | Aug 1999 | A |
| 5942223 | Bazer et al. | Aug 1999 | A |
| 5942253 | Gombotz et al. | Aug 1999 | A |
| 5945126 | Thanoo et al. | Aug 1999 | A |
| 5948430 | Zerbe et al. | Sep 1999 | A |
| 5958909 | Habener | Sep 1999 | A |
| D415073 | Meehan et al. | Oct 1999 | S |
| 5962023 | Jamiolkowski et al. | Oct 1999 | A |
| 5965168 | Mesens et al. | Oct 1999 | A |
| 5972370 | Eckenhoff et al. | Oct 1999 | A |
| 5972373 | Yajima et al. | Oct 1999 | A |
| 5976109 | Heruth | Nov 1999 | A |
| 5980945 | Ruiz | Nov 1999 | A |
| 5981719 | Woiszwillo et al. | Nov 1999 | A |
| 5984890 | Gast et al. | Nov 1999 | A |
| 5985305 | Peery et al. | Nov 1999 | A |
| 5989463 | Tracy et al. | Nov 1999 | A |
| 5997527 | Gumucio et al. | Dec 1999 | A |
| 5997902 | Maruyama et al. | Dec 1999 | A |
| 6007805 | Foster et al. | Dec 1999 | A |
| 6017545 | Modi | Jan 2000 | A |
| 6022561 | Carlsson et al. | Feb 2000 | A |
| 6023802 | King | Feb 2000 | A |
| 6029361 | Newman | Feb 2000 | A |
| 6056718 | Funderburk et al. | May 2000 | A |
| 6060450 | Soos et al. | May 2000 | A |
| 6069133 | Carlo et al. | May 2000 | A |
| 6074660 | Jamiolkowski et al. | Jun 2000 | A |
| 6074673 | Guillen | Jun 2000 | A |
| 6100346 | Jamiolkowski et al. | Aug 2000 | A |
| 6110503 | Rickey et al. | Aug 2000 | A |
| 6113938 | Chen et al. | Sep 2000 | A |
| 6113947 | Cleland et al. | Sep 2000 | A |
| 6120787 | Gustafsson et al. | Sep 2000 | A |
| 6124261 | Stevenson et al. | Sep 2000 | A |
| 6124281 | Lewis et al. | Sep 2000 | A |
| 6127520 | Ueda et al. | Oct 2000 | A |
| 6129761 | Hubbell | Oct 2000 | A |
| 6130200 | Brodbeck et al. | Oct 2000 | A |
| 6132420 | Dionne et al. | Oct 2000 | A |
| 6133249 | Hills | Oct 2000 | A |
| 6133429 | Davis et al. | Oct 2000 | A |
| 6147168 | Jamiolkowski et al. | Nov 2000 | A |
| 6156331 | Peery et al. | Dec 2000 | A |
| 6172046 | Albrecht | Jan 2001 | B1 |
| 6174547 | Dong et al. | Jan 2001 | B1 |
| 6177096 | Zerbe et al. | Jan 2001 | B1 |
| 6183461 | Matsuura et al. | Feb 2001 | B1 |
| 6187095 | Labrecque et al. | Feb 2001 | B1 |
| 6190350 | Davis et al. | Feb 2001 | B1 |
| 6190700 | Okada et al. | Feb 2001 | B1 |
| 6190702 | Takada et al. | Feb 2001 | B1 |
| 6191102 | DiMarchi et al. | Feb 2001 | B1 |
| 6204022 | Johnson et al. | Mar 2001 | B1 |
| 6217893 | Pellet et al. | Apr 2001 | B1 |
| 6217906 | Gumucio et al. | Apr 2001 | B1 |
| 6217908 | Mathiowitz et al. | Apr 2001 | B1 |
| 6218431 | Schoen et al. | Apr 2001 | B1 |
| 6224894 | Jamiolkowski et al. | May 2001 | B1 |
| 6235712 | Stevenson et al. | May 2001 | B1 |
| 6245349 | Yiv et al. | Jun 2001 | B1 |
| 6245357 | Edgren et al. | Jun 2001 | B1 |
| 6248112 | Gambale et al. | Jun 2001 | B1 |
| 6251435 | Jamiolkowski et al. | Jun 2001 | B1 |
| D445975 | Stratford | Jul 2001 | S |
| 6258377 | New et al. | Jul 2001 | B1 |
| 6261584 | Peery et al. | Jul 2001 | B1 |
| 6268343 | Knudsen et al. | Jul 2001 | B1 |
| 6270700 | Ignatious | Aug 2001 | B1 |
| 6270787 | Ayer | Aug 2001 | B1 |
| 6277413 | Sankaram | Aug 2001 | B1 |
| 6283949 | Roorda | Sep 2001 | B1 |
| 6284264 | Zerbe et al. | Sep 2001 | B1 |
| 6284727 | Kim et al. | Sep 2001 | B1 |
| 6287295 | Chen et al. | Sep 2001 | B1 |
| 6284725 | Coolidge et al. | Dec 2001 | B1 |
| 6329336 | Bridon et al. | Dec 2001 | B1 |
| 6331311 | Brodbeck et al. | Dec 2001 | B1 |
| 6372218 | Cummins, Jr. | Apr 2002 | B1 |
| 6372256 | Jamiolkowski et al. | Apr 2002 | B2 |
| 6375978 | Kleiner et al. | Apr 2002 | B1 |
| 6395292 | Peery et al. | May 2002 | B2 |
| 6403655 | Bezwada et al. | Jun 2002 | B1 |
| 6419952 | Wong et al. | Jul 2002 | B2 |
| 6433144 | Morris et al. | Aug 2002 | B1 |
| 6436091 | Harper et al. | Aug 2002 | B1 |
| 6447522 | Gambale et al. | Sep 2002 | B2 |
| 6451974 | Hansen | Sep 2002 | B1 |
| 6458385 | Jamiolkowski et al. | Oct 2002 | B2 |
| 6458387 | Scott et al. | Oct 2002 | B1 |
| 6458924 | Knudsen et al. | Oct 2002 | B2 |
| 6461605 | Cutler et al. | Oct 2002 | B1 |
| 6464688 | Harper et al. | Oct 2002 | B1 |
| 6468961 | Brodbeck et al. | Oct 2002 | B1 |
| 6471688 | Harper et al. | Oct 2002 | B1 |
| 6472512 | LaFleur et al. | Oct 2002 | B1 |
| 6485706 | McCoy et al. | Nov 2002 | B1 |
| 6495164 | Ramstack et al. | Dec 2002 | B1 |
| 6506724 | Hiles et al. | Jan 2003 | B1 |
| 6508808 | Carr et al. | Jan 2003 | B1 |
| 6514500 | Bridon et al. | Feb 2003 | B1 |
| 6514517 | Jamilolkowski et al. | Feb 2003 | B2 |
| 6524305 | Peterson et al. | Feb 2003 | B1 |
| 6528093 | Kamei et al. | Mar 2003 | B1 |
| 6528486 | Larsen et al. | Mar 2003 | B1 |
| D472896 | Peiker | Apr 2003 | S |
| 6541021 | Johnson et al. | Apr 2003 | B1 |
| 6544252 | Theeuwes et al. | Apr 2003 | B1 |
| 6547250 | Noble | Apr 2003 | B1 |
| 6551613 | Dong et al. | Apr 2003 | B1 |
| 6569420 | Chen et al. | May 2003 | B2 |
| 6572890 | Faour et al. | Jun 2003 | B2 |
| 6579851 | Goeke et al. | Jun 2003 | B2 |
| 6592887 | Zerbe et al. | Jul 2003 | B2 |
| 6593295 | Bridon et al. | Jul 2003 | B2 |
| 6635268 | Peery et al. | Oct 2003 | B2 |
| 6667061 | Ramstack et al. | Dec 2003 | B2 |
| 6670368 | Breault et al. | Dec 2003 | B1 |
| 6673767 | Brodbeck et al. | Jan 2004 | B1 |
| 6682522 | Carr et al. | Jan 2004 | B2 |
| 6703225 | Kojima et al. | Mar 2004 | B1 |
| 6703359 | Young et al. | Mar 2004 | B1 |
| 6706689 | Coolidge et al. | Mar 2004 | B2 |
| 6709671 | Zerbe et al. | Mar 2004 | B2 |
| 6720407 | Hughes et al. | Apr 2004 | B1 |
| 6730328 | Maskiwicz et al. | May 2004 | B2 |
| 6767887 | Hoffmann et al. | Jul 2004 | B1 |
| 6821949 | Bridon et al. | Nov 2004 | B2 |
| 6833256 | Pontzer et al. | Dec 2004 | B1 |
| 6835194 | Johnson et al. | Dec 2004 | B2 |
| 6840931 | Peterson et al. | Jan 2005 | B2 |
| 6849708 | Habener | Feb 2005 | B1 |
| 6849714 | Bridon et al. | Feb 2005 | B1 |
| 6858576 | Young et al. | Feb 2005 | B1 |
| 6872700 | Young et al. | Mar 2005 | B1 |
| 6875748 | Manthorpe et al. | Apr 2005 | B2 |
| 6887470 | Bridon et al. | May 2005 | B1 |
| 6887849 | Bridon et al. | May 2005 | B2 |
| 6899887 | Ayer | May 2005 | B2 |
| 6899898 | Albayrak | May 2005 | B2 |
| 6902744 | Kolterman et al. | Jun 2005 | B1 |
| 6903186 | Dong | Jun 2005 | B1 |
| 6913767 | Cleland et al. | Jul 2005 | B1 |
| 6923800 | Chen et al. | Aug 2005 | B2 |
| 6924264 | Prickett et al. | Aug 2005 | B1 |
| 6939556 | Lautenbach | Sep 2005 | B2 |
| 6956026 | Beeley et al. | Oct 2005 | B2 |
| 6969702 | Bertilsson et al. | Nov 2005 | B2 |
| 6976981 | Ayer | Dec 2005 | B2 |
| 6989366 | Beeley et al. | Jan 2006 | B2 |
| 6992065 | Okumu | Jan 2006 | B2 |
| 6997922 | Theeuwes et al. | Feb 2006 | B2 |
| 7014636 | Gilbert | Mar 2006 | B2 |
| 7022674 | DeFelippis et al. | Apr 2006 | B2 |
| 7041646 | Pan et al. | May 2006 | B2 |
| 7074423 | Fereira et al. | Jul 2006 | B2 |
| 7084243 | Glaesner et al. | Aug 2006 | B2 |
| 7101567 | Sano et al. | Sep 2006 | B1 |
| 7101843 | Glaesner et al. | Sep 2006 | B2 |
| 7112335 | Lautenbach | Sep 2006 | B2 |
| 7115569 | Beeley et al. | Oct 2006 | B2 |
| 7138375 | Beeley et al. | Nov 2006 | B2 |
| 7138486 | Habener et al. | Nov 2006 | B2 |
| 7141547 | Rosen et al. | Nov 2006 | B2 |
| 7144863 | DeFelippis et al. | Dec 2006 | B2 |
| 7153825 | Young et al. | Dec 2006 | B2 |
| 7157555 | Beeley et al. | Jan 2007 | B1 |
| 7163688 | Peery et al. | Jan 2007 | B2 |
| 7163697 | Hanes et al. | Jan 2007 | B2 |
| 7199217 | DiMarchi et al. | Apr 2007 | B2 |
| 7205409 | Pei et al. | Apr 2007 | B2 |
| 7207982 | Dionne et al. | Apr 2007 | B2 |
| 7241457 | Chen et al. | Jul 2007 | B2 |
| 7258869 | Berry et al. | Aug 2007 | B1 |
| D555589 | Hussaini et al. | Nov 2007 | S |
| 7297761 | Beeley et al. | Nov 2007 | B2 |
| 7316680 | Gilbert | Jan 2008 | B2 |
| 7393827 | Nadler | Jul 2008 | B2 |
| 7407499 | Trautman | Aug 2008 | B2 |
| 7442682 | Kitaura et al. | Oct 2008 | B2 |
| 7456254 | Wright et al. | Nov 2008 | B2 |
| 7459432 | Cowley et al. | Dec 2008 | B2 |
| 7521423 | Young et al. | Apr 2009 | B2 |
| 7563871 | Wright et al. | Jul 2009 | B2 |
| 7589169 | Bolotin | Sep 2009 | B2 |
| 7612176 | Wright et al. | Nov 2009 | B2 |
| 7635463 | Bolotin et al. | Dec 2009 | B2 |
| D608447 | Meyer et al. | Jan 2010 | S |
| 7655254 | Dennis et al. | Feb 2010 | B2 |
| 7655257 | Peery et al. | Feb 2010 | B2 |
| 7666835 | Bloom et al. | Feb 2010 | B2 |
| 7682356 | Alessi et al. | Mar 2010 | B2 |
| 7727519 | Moran | Jun 2010 | B2 |
| 7731947 | Eliaz et al. | Jun 2010 | B2 |
| 7736665 | Patel et al. | Jun 2010 | B2 |
| 7741269 | Young et al. | Jun 2010 | B2 |
| 7790140 | Bolotin | Sep 2010 | B2 |
| 7825091 | Bloom et al. | Nov 2010 | B2 |
| 7829109 | Chen et al. | Nov 2010 | B2 |
| 7833543 | Gibson et al. | Nov 2010 | B2 |
| 7879028 | Alessi et al. | Feb 2011 | B2 |
| 7879794 | Berry et al. | Apr 2011 | B2 |
| 7919109 | Berry et al. | Apr 2011 | B2 |
| D638478 | Block | May 2011 | S |
| 7928065 | Rohloff et al. | Jun 2011 | B2 |
| 7964183 | Eliaz et al. | Jun 2011 | B2 |
| 8039432 | Bridon et al. | Oct 2011 | B2 |
| 7959938 | Lautenbach et al. | Nov 2011 | B2 |
| 8048438 | Berry et al. | Nov 2011 | B2 |
| 8052996 | Lautenbach et al. | Nov 2011 | B2 |
| 8058233 | Cowley et al. | Nov 2011 | B2 |
| 8101576 | Bloom | Jan 2012 | B2 |
| 8114430 | Rohloff et al. | Feb 2012 | B2 |
| 8114437 | Rohloff et al. | Feb 2012 | B2 |
| 8158150 | Lautenbach et al. | Apr 2012 | B2 |
| 8173150 | Berry et al. | May 2012 | B2 |
| 8202836 | Moore et al. | Jun 2012 | B2 |
| 8206745 | Rohloff et al. | Jun 2012 | B2 |
| 8211467 | Rohloff et al. | Jul 2012 | B2 |
| 8217001 | Cowley et al. | Jul 2012 | B2 |
| 8231859 | Bolotin et al. | Jul 2012 | B2 |
| 8257682 | Bolotin et al. | Sep 2012 | B2 |
| 8257691 | Eliaz et al. | Sep 2012 | B2 |
| 8262667 | Silver et al. | Sep 2012 | B1 |
| 8263545 | Bloom | Sep 2012 | B2 |
| 8263736 | Berry | Sep 2012 | B2 |
| 8268341 | Berry | Sep 2012 | B2 |
| 8273365 | Lautenbach et al. | Sep 2012 | B2 |
| 8273713 | Pittner et al. | Sep 2012 | B2 |
| D669589 | Delaey | Oct 2012 | S |
| 8277776 | Bolotin et al. | Oct 2012 | B2 |
| 8278267 | Weyer et al. | Oct 2012 | B2 |
| 8288338 | Alessi et al. | Oct 2012 | B2 |
| 8298561 | Alessi et al. | Oct 2012 | B2 |
| 8299025 | Alessi et al. | Oct 2012 | B2 |
| 8343140 | Alessi et al. | Jan 2013 | B2 |
| 8367095 | Lautenbach et al. | Feb 2013 | B2 |
| 8372424 | Berry et al. | Feb 2013 | B2 |
| D678889 | Chiu | Mar 2013 | S |
| 8398967 | Eliaz et al. | Mar 2013 | B2 |
| 8440226 | Rohloff et al. | May 2013 | B2 |
| 8460694 | Rohloff et al. | Jun 2013 | B2 |
| 8470353 | Lautenbach et al. | Jun 2013 | B2 |
| 8801700 | Alessi et al. | Aug 2014 | B2 |
| 8815802 | Kalthoff | Aug 2014 | B2 |
| 8858621 | Oba et al. | Oct 2014 | B2 |
| 8865202 | Zerbe et al. | Oct 2014 | B2 |
| 8888745 | Van Der Graaf et al. | Nov 2014 | B2 |
| 8926595 | Alessi | Jan 2015 | B2 |
| 8940316 | Alessi | Jan 2015 | B2 |
| 8992961 | Berry et al. | Mar 2015 | B2 |
| 8992962 | Lautenbach et al. | Mar 2015 | B2 |
| 9044209 | Dayton et al. | Jun 2015 | B2 |
| 9078900 | Kuzma et al. | Jul 2015 | B2 |
| 9095553 | Rohloff et al. | Aug 2015 | B2 |
| 9241722 | Yu | Jan 2016 | B2 |
| D750764 | DeSocio | Mar 2016 | S |
| 9332995 | Russo | May 2016 | B2 |
| 9526763 | Rohloff et al. | Dec 2016 | B2 |
| 9539200 | Lautenbach | Jan 2017 | B2 |
| 9572889 | Alessi et al. | Feb 2017 | B2 |
| D789539 | Kleiner et al. | Jun 2017 | S |
| D789540 | Gyorgy | Jun 2017 | S |
| 9682127 | Alessi et al. | Jun 2017 | B2 |
| RE46577 | Collins et al. | Oct 2017 | E |
| 9889085 | Alessi et al. | Feb 2018 | B1 |
| 20010012511 | Bezwada et al. | Aug 2001 | A1 |
| 20010021377 | Jamiolkowski et al. | Sep 2001 | A1 |
| 20010021822 | Ayer | Sep 2001 | A1 |
| 20010022974 | Ayer | Sep 2001 | A1 |
| 20010026793 | Jamiolkowski et al. | Oct 2001 | A1 |
| 20010027311 | Chen et al. | Oct 2001 | A1 |
| 20010031790 | Beisswenger | Nov 2001 | A1 |
| 20010036472 | Wong et al. | Nov 2001 | A1 |
| 20010040326 | Balczun | Nov 2001 | A1 |
| 20020001631 | Okumu | Jan 2002 | A1 |
| 20020004481 | Cleland et al. | Jan 2002 | A1 |
| 20020012818 | Ruppi et al. | Jan 2002 | A1 |
| 20020034532 | Brodbeck et al. | Mar 2002 | A1 |
| 20020037309 | Jaworowicz et al. | Mar 2002 | A1 |
| 20020048600 | Bhatt et al. | Apr 2002 | A1 |
| 20020098180 | Lei | Jul 2002 | A1 |
| 20020136848 | Yoshii et al. | Sep 2002 | A1 |
| 20020137666 | Beeley et al. | Sep 2002 | A1 |
| 20020141985 | Pittner et al. | Oct 2002 | A1 |
| 20020197185 | Jamiolkowski et al. | Dec 2002 | A1 |
| 20020197235 | Moran | Dec 2002 | A1 |
| 20030032947 | Harper et al. | Feb 2003 | A1 |
| 20030044467 | Brodbeck et al. | Mar 2003 | A1 |
| 20030045454 | Okumu et al. | Mar 2003 | A1 |
| 20030059376 | Libbey et al. | Mar 2003 | A1 |
| 20030060425 | Ahlem et al. | Mar 2003 | A1 |
| 20030097121 | Babcock et al. | Jun 2003 | A1 |
| 20030104063 | Babcock et al. | Jun 2003 | A1 |
| 20030108608 | Berry et al. | Jun 2003 | A1 |
| 20030108609 | Berry et al. | Jun 2003 | A1 |
| 20030113380 | Ramstack et al. | Jun 2003 | A1 |
| 20030114837 | Peterson et al. | Jun 2003 | A1 |
| 20030118660 | Rickey et al. | Jun 2003 | A1 |
| 20030138403 | Drustrup | Jul 2003 | A1 |
| 20030138491 | Tracy et al. | Jul 2003 | A1 |
| 20030157178 | Chen et al. | Aug 2003 | A1 |
| 20030170289 | Chen et al. | Sep 2003 | A1 |
| 20030180364 | Chen et al. | Sep 2003 | A1 |
| 20030186858 | Arentsen | Oct 2003 | A1 |
| 20030191099 | Bohlmann et al. | Oct 2003 | A1 |
| 20030211974 | Brodbeck et al. | Nov 2003 | A1 |
| 20030215515 | Truong-Le et al. | Nov 2003 | A1 |
| 20040001689 | Goldsmith et al. | Jan 2004 | A1 |
| 20040001889 | Chen et al. | Jan 2004 | A1 |
| 20040002442 | Pan et al. | Jan 2004 | A1 |
| 20040022859 | Chen et al. | Feb 2004 | A1 |
| 20040024068 | Chen et al. | Feb 2004 | A1 |
| 20040024069 | Chen et al. | Feb 2004 | A1 |
| 20040029784 | Hathaway | Feb 2004 | A1 |
| 20040039376 | Peery et al. | Feb 2004 | A1 |
| 20040097906 | Fereira et al. | May 2004 | A1 |
| 20040101557 | Gibson et al. | May 2004 | A1 |
| 20040102762 | Gilbert | May 2004 | A1 |
| 20040115236 | Chan et al. | Jun 2004 | A1 |
| 20040142867 | Oi et al. | Jul 2004 | A1 |
| 20040142902 | Struijker-Boudier | Jul 2004 | A1 |
| 20040151753 | Chen et al. | Aug 2004 | A1 |
| 20040157951 | Wolf | Aug 2004 | A1 |
| 20040198654 | Glaesner et al. | Oct 2004 | A1 |
| 20040209801 | Brand et al. | Oct 2004 | A1 |
| 20040224903 | Berry et al. | Nov 2004 | A1 |
| 20040225113 | LaFleur et al. | Nov 2004 | A1 |
| 20040243106 | Ayer | Dec 2004 | A1 |
| 20040265273 | Li et al. | Dec 2004 | A1 |
| 20040266683 | Hathaway et al. | Dec 2004 | A1 |
| 20040266692 | Young et al. | Dec 2004 | A1 |
| 20050004557 | Russell | Jan 2005 | A1 |
| 20050008661 | Fereira et al. | Jan 2005 | A1 |
| 20050009742 | Bertilsson et al. | Jan 2005 | A1 |
| 20050010196 | Fereira et al. | Jan 2005 | A1 |
| 20050070883 | Brown et al. | Mar 2005 | A1 |
| 20050070927 | Feinberg | Mar 2005 | A1 |
| 20050079200 | Rathenow et al. | Apr 2005 | A1 |
| 20050079202 | Chen et al. | Apr 2005 | A1 |
| 20050010942 | Eliaz et al. | May 2005 | A1 |
| 20050095284 | Trautman | May 2005 | A1 |
| 20050101943 | Ayer et al. | May 2005 | A1 |
| 20050106214 | Chen | May 2005 | A1 |
| 20050112188 | Eliaz et al. | May 2005 | A1 |
| 20050118206 | Luk et al. | Jun 2005 | A1 |
| 20050118221 | Blakely et al. | Jun 2005 | A1 |
| 20050131386 | Freeman et al. | Jun 2005 | A1 |
| 20050131389 | Peterson et al. | Jun 2005 | A1 |
| 20050175701 | Pan et al. | Aug 2005 | A1 |
| 20050201980 | Moran | Sep 2005 | A1 |
| 20050215475 | Ong et al. | Sep 2005 | A1 |
| 20050216087 | Zucherman, Jr. et al. | Sep 2005 | A1 |
| 20050266087 | Junnarkar et al. | Dec 2005 | A1 |
| 20050271702 | Wright et al. | Dec 2005 | A1 |
| 20050276856 | Fereira et al. | Dec 2005 | A1 |
| 20050281879 | Chen et al. | Dec 2005 | A1 |
| 20060013879 | Brodbeck et al. | Jan 2006 | A9 |
| 20060014678 | Cowley et al. | Jan 2006 | A1 |
| 20060030526 | Liu et al. | Feb 2006 | A1 |
| 20060069029 | Kolterman et al. | Mar 2006 | A1 |
| 20060073182 | Wong et al. | Apr 2006 | A1 |
| 20060084604 | Kitaura et al. | Apr 2006 | A1 |
| 20060084922 | Botha | Apr 2006 | A1 |
| 20060094652 | Levy et al. | May 2006 | A1 |
| 20060094693 | Aziz et al. | May 2006 | A1 |
| 20060106399 | Taras et al. | May 2006 | A1 |
| 20060141040 | Chen et al. | Jun 2006 | A1 |
| 20060142234 | Chen et al. | Jun 2006 | A1 |
| 20060160736 | Nadler | Jul 2006 | A1 |
| 20060178304 | Juul-Mortensen et al. | Aug 2006 | A1 |
| 20060193918 | Rohloff et al. | Aug 2006 | A1 |
| 20060216242 | Rohloff et al. | Sep 2006 | A1 |
| 20060224145 | Gills | Oct 2006 | A1 |
| 20060233841 | Brodbeck et al. | Oct 2006 | A1 |
| 20060246138 | Rohloff et al. | Nov 2006 | A1 |
| 20060251618 | Dennis et al. | Nov 2006 | A1 |
| 20060263433 | Ayer et al. | Nov 2006 | A1 |
| 20060264890 | Moberg et al. | Nov 2006 | A1 |
| 20060280795 | Penhasi et al. | Dec 2006 | A1 |
| 20060293232 | Levy et al. | Dec 2006 | A1 |
| 20070027105 | Junnarkar et al. | Feb 2007 | A1 |
| 20070149011 | Kent et al. | Jun 2007 | A1 |
| 20070166352 | Wright et al. | Jul 2007 | A1 |
| 20070207958 | Bridon et al. | Sep 2007 | A1 |
| 20070248572 | Moran et al. | Oct 2007 | A1 |
| 20070281024 | Lautenbach et al. | Dec 2007 | A1 |
| 20080020016 | Li et al. | Jan 2008 | A1 |
| 20080038316 | Wong et al. | Feb 2008 | A1 |
| 20080064636 | Bloom et al. | Mar 2008 | A1 |
| 20080065090 | Scribner et al. | Mar 2008 | A1 |
| 20080091176 | Alessi et al. | Apr 2008 | A1 |
| 20080110515 | Angelosanto et al. | May 2008 | A1 |
| 20080112994 | Junnarkar et al. | May 2008 | A1 |
| 20080200383 | Jennings et al. | Aug 2008 | A1 |
| 20080207512 | Roth et al. | Aug 2008 | A1 |
| 20080208194 | Bickenbach | Aug 2008 | A1 |
| 20080226625 | Berry et al. | Sep 2008 | A1 |
| 20080226689 | Berry et al. | Sep 2008 | A1 |
| 20080260838 | Hokenson et al. | Oct 2008 | A1 |
| 20080260840 | Alessi et al. | Oct 2008 | A1 |
| 20080269725 | Deem et al. | Oct 2008 | A1 |
| 20080312157 | Levy et al. | Dec 2008 | A1 |
| 20090022727 | Houston et al. | Jan 2009 | A1 |
| 20090036364 | Levy et al. | Feb 2009 | A1 |
| 20090042781 | Petersen et al. | Feb 2009 | A1 |
| 20090074734 | Rottiers | Mar 2009 | A1 |
| 20090087408 | Berry et al. | Apr 2009 | A1 |
| 20090156474 | Roth et al. | Jun 2009 | A1 |
| 20090163447 | Maggio | Jun 2009 | A1 |
| 20090186817 | Ghosh et al. | Jul 2009 | A1 |
| 20090202481 | Li et al. | Aug 2009 | A1 |
| 20090202608 | Alessi et al. | Aug 2009 | A1 |
| 20090209460 | Young et al. | Aug 2009 | A1 |
| 20090210019 | Kim et al. | Aug 2009 | A1 |
| 20090215694 | Kolterman et al. | Aug 2009 | A1 |
| 20090234392 | Dziedzic | Sep 2009 | A1 |
| 20090247463 | Wright et al. | Oct 2009 | A1 |
| 20090254143 | Tweden et al. | Oct 2009 | A1 |
| 20090286723 | Levy et al. | Nov 2009 | A1 |
| 20090312246 | Baron et al. | Dec 2009 | A1 |
| 20100092566 | Alessi et al. | Apr 2010 | A1 |
| 20100105627 | Salama et al. | Apr 2010 | A1 |
| 20100144621 | Kim et al. | Jun 2010 | A1 |
| 20100185184 | Alessi et al. | Jul 2010 | A1 |
| 20100297209 | Rohloff et al. | Nov 2010 | A1 |
| 20100298840 | Schwartz | Nov 2010 | A1 |
| 20110076317 | Alessi et al. | Mar 2011 | A1 |
| 20110091527 | Moonen et al. | Apr 2011 | A1 |
| 20110104111 | Rohloff et al. | May 2011 | A1 |
| 20110152181 | Alsina-Fernandez et al. | Jun 2011 | A1 |
| 20110152182 | Alsina-Fernandez et al. | Jun 2011 | A1 |
| 20110160708 | Berry et al. | Jun 2011 | A1 |
| 20110166554 | Alessi et al. | Jul 2011 | A1 |
| 20110264077 | Rohloff et al. | Oct 2011 | A1 |
| 20110306549 | Tatarkiewicz et al. | Dec 2011 | A1 |
| 20120208755 | Leung | Aug 2012 | A1 |
| 20130030417 | Alessi | Jan 2013 | A1 |
| 20130034210 | Rohloff et al. | Feb 2013 | A1 |
| 20130052237 | Eliaz et al. | Feb 2013 | A1 |
| 20140058425 | Porat | Feb 2014 | A1 |
| 20140121741 | Bennett et al. | May 2014 | A1 |
| 20140257272 | Clark, III et al. | Sep 2014 | A1 |
| 20140378900 | Alessi et al. | Dec 2014 | A1 |
| 20150057227 | Leung | Feb 2015 | A1 |
| 20150111818 | Alessi et al. | Apr 2015 | A1 |
| 20150133791 | Sato et al. | May 2015 | A1 |
| 20150231062 | Lautenbach et al. | Aug 2015 | A1 |
| 20150231256 | Berry et al. | Aug 2015 | A1 |
| 20150297509 | Schwarz | Oct 2015 | A1 |
| 20160022582 | Alessi et al. | Jan 2016 | A1 |
| 20160030337 | Kuzma et al. | Feb 2016 | A1 |
| 20160354115 | Smith et al. | Dec 2016 | A1 |
| 20160354305 | Alessi et al. | Dec 2016 | A1 |
| 20170056476 | Rohloff et al. | Mar 2017 | A1 |
| 20170079906 | Alessi et al. | Mar 2017 | A1 |
| 20170119854 | Alessi et al. | May 2017 | A1 |
| 20170119855 | Berry et al. | May 2017 | A1 |
| 20170181964 | Lautenbach et al. | Jun 2017 | A1 |
| 20170273706 | Mirza et al. | Sep 2017 | A1 |
| 20170319470 | Eliaz et al. | Nov 2017 | A1 |
| 20170319662 | Berry et al. | Nov 2017 | A1 |
| 20170348392 | Rohloff et al. | Dec 2017 | A1 |
| 20170368145 | Alessi et al. | Dec 2017 | A1 |
| 20180009871 | Blackwell et al. | Jan 2018 | A1 |
| 20180185451 | Young et al. | Jul 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 0052510 | May 1982 | EP |
| 0079405 | May 1983 | EP |
| 0254394 | Jan 1988 | EP |
| 0295411 | Dec 1988 | EP |
| 0302582 | Feb 1989 | EP |
| 0368339 | May 1990 | EP |
| 0373867 | Jun 1990 | EP |
| 0431942 | Jun 1991 | EP |
| 0486959 | May 1992 | EP |
| 0521586 | Jan 1993 | EP |
| 0596161 | May 1994 | EP |
| 0379147 | Sep 1994 | EP |
| 0627231 | Dec 1994 | EP |
| 0729747 | May 1997 | EP |
| 0771817 | May 1997 | EP |
| 0841359 | May 1998 | EP |
| 0767689 | Jun 1999 | EP |
| 1046399 | Oct 2000 | EP |
| 1084703 | Mar 2001 | EP |
| 1300129 | Apr 2003 | EP |
| 1300173 | Apr 2003 | EP |
| 1600187 | Jan 2009 | EP |
| 2133073 | Dec 2009 | EP |
| 2020990 | Sep 2010 | EP |
| 640907 | Jul 1928 | FR |
| 1049104 | Nov 1966 | GB |
| 1518683 | Jul 1978 | GB |
| 2501400 | Oct 2013 | GB |
| H02124814 | May 1990 | JP |
| H07196479 | Aug 1995 | JP |
| 9241153 | Sep 1997 | JP |
| 11-100353 | Apr 1999 | JP |
| 2006213727 | Aug 2006 | JP |
| 9100160 | Aug 1992 | NL |
| 592113 | Aug 2012 | NZ |
| 200634060 | Oct 2006 | TW |
| WO-1989003678 | May 1989 | WO |
| WO-1990013285 | Nov 1990 | WO |
| WO-1990013361 | Nov 1990 | WO |
| WO-1990013780 | Nov 1990 | WO |
| WO 9107160 | May 1991 | WO |
| WO-1992019241 | Nov 1992 | WO |
| WO 9306819 | Apr 1993 | WO |
| WO 9306821 | Apr 1993 | WO |
| WO 93008832 | May 1993 | WO |
| WO 9309763 | May 1993 | WO |
| WO 9323083 | Nov 1993 | WO |
| WO 9409743 | May 1994 | WO |
| WO 1994010982 | May 1994 | WO |
| WO 9421262 | Sep 1994 | WO |
| WO 9501167 | Jan 1995 | WO |
| WO 9509006 | Apr 1995 | WO |
| WO 9509007 | Apr 1995 | WO |
| WO-1995013799 | May 1995 | WO |
| WO 9534285 | Dec 1995 | WO |
| WO 96001134 | Jan 1996 | WO |
| WO 96003116 | Feb 1996 | WO |
| WO-1996036317 | Nov 1996 | WO |
| WO 9639142 | Dec 1996 | WO |
| WO 9640049 | Dec 1996 | WO |
| WO 9640139 | Dec 1996 | WO |
| WO 9640355 | Dec 1996 | WO |
| WO-1996040049 | Dec 1996 | WO |
| WO 9715289 | May 1997 | WO |
| WO 9715296 | May 1997 | WO |
| WO 9728181 | Aug 1997 | WO |
| WO-1997031943 | Sep 1997 | WO |
| WO-1997044039 | Nov 1997 | WO |
| WO 9746204 | Dec 1997 | WO |
| WO 9747339 | Dec 1997 | WO |
| WO 9800152 | Jan 1998 | WO |
| WO 9800157 | Jan 1998 | WO |
| WO 9800158 | Jan 1998 | WO |
| WO 9802169 | Jan 1998 | WO |
| WO-1997041837 | Feb 1998 | WO |
| WO-1998007412 | Feb 1998 | WO |
| WO 9816250 | Apr 1998 | WO |
| WO 9817315 | Apr 1998 | WO |
| WO 9820930 | May 1998 | WO |
| WO 9827960 | Jul 1998 | WO |
| WO 98027962 | Jul 1998 | WO |
| WO 9827963 | Jul 1998 | WO |
| WO 98030231 | Jul 1998 | WO |
| WO 9832463 | Jul 1998 | WO |
| WO-1998030231 | Jul 1998 | WO |
| WO 9842317 | Oct 1998 | WO |
| WO 9847487 | Oct 1998 | WO |
| WO 9851282 | Nov 1998 | WO |
| WO 9903453 | Jan 1999 | WO |
| WO 9904767 | Feb 1999 | WO |
| WO 99004768 | Feb 1999 | WO |
| WO-1999012549 | Mar 1999 | WO |
| WO 9916419 | Apr 1999 | WO |
| WO 99025728 | May 1999 | WO |
| WO 9929306 | Jun 1999 | WO |
| WO 99033446 | Jul 1999 | WO |
| WO 9933449 | Jul 1999 | WO |
| WO 9939700 | Aug 1999 | WO |
| WO 99040788 | Aug 1999 | WO |
| WO 99044659 | Sep 1999 | WO |
| WO 99062501 | Dec 1999 | WO |
| WO 99064061 | Dec 1999 | WO |
| WO 00013663 | Mar 2000 | WO |
| WO 00029206 | May 2000 | WO |
| WO 00038652 | Jul 2000 | WO |
| WO 00039280 | Jul 2000 | WO |
| WO 00040273 | Jul 2000 | WO |
| WO 00041548 | Jul 2000 | WO |
| WO 00045790 | Aug 2000 | WO |
| WO 00054745 | Sep 2000 | WO |
| WO-2000059476 | Oct 2000 | WO |
| WO 00066138 | Nov 2000 | WO |
| WO 00067728 | Nov 2000 | WO |
| WO-2000066087 | Nov 2000 | WO |
| WO-2001019345 | Mar 2001 | WO |
| WO 2001028525 | Apr 2001 | WO |
| WO 01043528 | Jun 2001 | WO |
| WO 01051041 | Jul 2001 | WO |
| WO 0178683 | Oct 2001 | WO |
| WO 02028366 | Apr 2002 | WO |
| WO 02036072 | May 2002 | WO |
| WO 02043800 | Jun 2002 | WO |
| WO 02045752 | Jun 2002 | WO |
| WO 0247716 | Jun 2002 | WO |
| WO 02067895 | Sep 2002 | WO |
| WO 02069983 | Sep 2002 | WO |
| WO 0276344 | Oct 2002 | WO |
| WO 02085428 | Oct 2002 | WO |
| WO 03000230 | Jan 2003 | WO |
| WO 03007981 | Jan 2003 | WO |
| WO 03011892 | Feb 2003 | WO |
| WO 03024357 | Mar 2003 | WO |
| WO 03024503 | Mar 2003 | WO |
| WO-2003020245 | Mar 2003 | WO |
| WO 03030923 | Apr 2003 | WO |
| WO 03041684 | May 2003 | WO |
| WO 03041757 | May 2003 | WO |
| WO 03053400 | Jul 2003 | WO |
| WO-2003066585 | Aug 2003 | WO |
| WO 03072113 | Sep 2003 | WO |
| WO 03072133 | Sep 2003 | WO |
| WO 04002565 | Jan 2004 | WO |
| WO-2004034975 | Apr 2004 | WO |
| WO-2004035754 | Apr 2004 | WO |
| WO-2004035762 | Apr 2004 | WO |
| WO 2004036186 | Apr 2004 | WO |
| WO 04052336 | Jun 2004 | WO |
| WO 04056338 | Jul 2004 | WO |
| WO 04089335 | Oct 2004 | WO |
| WO 2004103342 | Dec 2004 | WO |
| WO 05048930 | Jun 2005 | WO |
| WO 05048952 | Jun 2005 | WO |
| WO 05102293 | Nov 2005 | WO |
| WO-2005102293 | Nov 2005 | WO |
| WO 2005110425 | Nov 2005 | WO |
| WO 06017772 | Feb 2006 | WO |
| WO 06023526 | Mar 2006 | WO |
| WO 06081279 | Aug 2006 | WO |
| WO 06083761 | Aug 2006 | WO |
| WO 06084139 | Aug 2006 | WO |
| WO 06086727 | Aug 2006 | WO |
| WO 06101815 | Sep 2006 | WO |
| WO 06111169 | Oct 2006 | WO |
| WO-2006131730 | Dec 2006 | WO |
| WO 07024700 | Mar 2007 | WO |
| WO 07056681 | May 2007 | WO |
| WO 07075534 | Jul 2007 | WO |
| WO 07084460 | Jul 2007 | WO |
| WO 07133778 | Nov 2007 | WO |
| WO 07140416 | Dec 2007 | WO |
| WO 08021133 | Feb 2008 | WO |
| WO-2008041245 | Apr 2008 | WO |
| WO 08061355 | May 2008 | WO |
| WO-2008086086 | Jul 2008 | WO |
| WO 08133908 | Nov 2008 | WO |
| WO 08134425 | Nov 2008 | WO |
| WO 09109927 | Sep 2009 | WO |
| WO-2009143285 | Nov 2009 | WO |
| WO 2013004983 | Jan 2013 | WO |
| Entry |
|---|
| Adolf, “Human interferon omega-a review,” Mult. Sclr. 1:S44-47 (1995). |
| Costantino et al., “Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability,” J. Pharm. Sci. 91:388-395 (2002). |
| Henry et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010). |
| Huggins et al., “Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses,” Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984). |
| Ishiwata et al., “Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs,” J. Vet. Med. Sci. 60(8):911-917 (1998). |
| Johnson et al., “How interferons fight disease,” Sci. Am. 270(5):68-75 (May 1994). |
| Lublin et al., “Defining the clinical course of multiple sclerosis: results of an international survey,” Neurology. 46:907-911 (1996). |
| Madsbad, “Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results,” Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009). |
| Nielsen, “Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes,” Drug Discovery Today 10(10):703-710 (May 15, 2005). |
| Palmeri et al., “5-Fluorouracil and recombinant α-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study,” J. Chemotherapy 2(5):327-330 (Oct. 1990). |
| Patti et al., “Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study,” Acta. Neurol. Scand. 100:283-289 (1999). |
| Paty et al., “Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis,” Neurology 43:662-667 (1993). |
| PCT International Search Report for PCT/US2009/000916, 4 pages (dated Aug. 12, 2009). |
| “Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1,” NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release). |
| Quianzon et al., “Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes,” US Endocrinology 7(2):104-109 (2011). |
| Ratner et al., “Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial,” Diabetic Medicine 27(9):1024-1032 (Sep. 2010). |
| Roberts et al., “The Evolution of the Type I Interferons1,” J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998). |
| Rohloff et al., “DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months,” J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008). |
| “Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope”, http://patentscope.wipo.int/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012). |
| Shire et al., “Challenges in the Development of High Protein Concentration Formulations,” J. Pharm. Sci. 93:1390-1402 (2004). |
| Smith, “Peripheral Neuro-hormones as a Strategy to Treat Obesity,” oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007). |
| Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (dated Apr. 15, 2011). |
| Zhang et al., “Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers,” Current Physician 2(12):45-46 (1997). |
| Pratley et al., “Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors,” Rev. Diabet. Stud., 5(2):73-94 (2008). |
| Gonzalez, et al., “Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico,” Salud Publica Mex 55:462-468 (2013). |
| Ahn et al., “A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning” Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116. |
| “Abstracts 2007,” Diabetologia Clinical & Experimental Diabetes & Metabolism, Springer, Berlin, Germany, vol. 50 S243 (Aug. 21, 2007) (paragraph [0586]) (X0002538652). |
| Jetschmann et al., “Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C,” Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454). |
| Bray, “Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin,” (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME). |
| “Implantable infusion pumps: technology poised for takeoff,” BBI Newsletter 17(12):209-211 (Dec. 1994). |
| Adamson et al., “Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer,” J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997). |
| Adolf et al., “Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN,” Virology 175(2):410-471 (Apr. 1990). |
| Adolf et al., “Antigenic structure of human interferon ωl (Interferon αll1): comparison with other human interferons,” J. Gen. Virol. 68(6):1669-1676 (Jun. 1987). |
| Adolf et al., “Purification and characterization of natural human interferon ω1,” J. Bio. Chem. 265(16):9290-9295 (Jun. 1990). |
| Adolf et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,” Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991). |
| Andrx Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005). |
| ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984). |
| Ansel et al., “Dosage Form Design: Pharmaceutical and Formulation Considerations,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999). |
| Ansel et al., “Modified-Release Dosage Forms and Drug Delivery Systems,” Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999). |
| Aulitzky, “Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama,” Journal of Clinical Oncology 7(12):1875-1884 (1989). |
| Hauck, “Engineer's Guide to Plastics,” Materials Engineering 5(72):38-45 (Jul. 17, 1972). |
| Bailon et al., “Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C,” Bioconjugate Chemistry 12(2):195-202 (2001). |
| Bakan et al., “Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography,” J. Pharm. Sci., 85(9):908-914 (1996). |
| Bakhtiar et al, “Taking Delivery,” Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems). |
| Balkwill, F., “Interferons,” Lancet 1(8646):1060-1063 (May 1989). |
| Bauer et al., “Non-aqueous emulsions as vehicles for capsule fillings,” Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984). |
| Bekkering et al., “Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model,” Hepatology 33(2):419-423 (Feb. 2001). |
| Bell et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature 302:716-718 (1983). |
| Bell et al, “Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin,” Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995). |
| Bertoncello et al., “Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil,” Int. J. Radiat. Biol. 67(1):57-64 (1995). |
| Bohlinder et al., “Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system,” Euro. J. Pharm. Sci. 2(4):271-279 (1994). |
| Bolinger et al., “Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders,” Clin. Pharm. 11(10):834-850 (Oct. 1992). |
| Bonkovsky et al., “Outcomes research in chronic viral hepatitis C: effects of interferon therapy,” Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000). |
| Borden et al., “Second-generation interferons for cancer: clinical targets,” Semin. Cancer Biol. 10(2):125-144 (Apr. 2000). |
| Boué et al., “Antiviral and antiluteolytic activity of recombinant bovine IFN-ω1 obtained from Pichia pastoris,” J. Interferon & Cytokine Res. 20:677-683 (2000). |
| Buckwold et. al. “Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses,” Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006). |
| Cantor, “Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence,” J. Chem. Physics 104(20):8082-8095 (1996). |
| CAS No. 56-81-5 (Nov. 16, 1984). |
| Chang et al., “Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer,” Pharm. Tech. 20(1):80-84 (1996). |
| Chapman et al., “Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins),” Chem. & Physics of Lipids 1(5):445-475 (1967). |
| Chaumeil, “Micronization: a method of improving the bioavailability of poorly soluble drugs,” Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998). |
| Clark et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol. 173(1):68-75 (1983). |
| Condino-Neto, “Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation,” Blood 95(11):3548-3554 (Jun. 2000). |
| Darney, “Subdermal progestin implant contraception,” Current Opinion in Obstetrics & Gynecology 3:470-476 (1991). |
| DAS et al., “Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues,” BioPharm, 2(11):44-51 (1999). |
| Dash et al., “Therapeutic applications of implantable drug delivery systems,” Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998). |
| Davis et al., “Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570 ). |
| Deacon et al., “GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion,” Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002). |
| Desai et al., “Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor,” J. Am. Chem. Soc. 116(21):9420-9422 (1994). |
| Di Marco et al., “Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569). |
| Dorr et al., “Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days,” J. Interferon Res. 8:717-725 (1988). |
| Uhlig et al., “The electro-osmotic acutation of implantable insulin micropumps,” J. Biomed. Materials Res. 17:931-943 (1983). |
| Efendic et al., “Overview of incretin hormones,” Horm. Metab. Res., 36(11-12):742-746 (2004). |
| Eissele et al., “Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide,” Life Sci., 55(8):629-634 (1994). |
| Elias et al., “Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study,” Cancer 89(3):597-603 (Aug. 2000). |
| Eng et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,” J. Biol. Chem., 267(11):7402-7405 (1992). |
| Eng et al., “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” J. Biol. Chem., 265(33):20259-20262 (1990). |
| Eppstein et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,” PNAS USA 82:3688-3692 (1985). |
| Eros et al., “Multiple phase emulsions as controlled drug delivery therapeutic systems,” Proc.-Conf. Colloid Chem. 193-196 (1993). |
| Fang et al., “The impact of baseline liver histology on virologic response to interferon α-2b±ρ ribavirin therapy in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572). |
| Felker et al., “The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface,” J. Nutritional Biochem. 4(1):630-634 (1993). |
| Ferenci et al, “Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977). |
| Fontaine et al., “Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon α,” Lancet 356(9223):41 (Jul. 2000). |
| Franchetti et al., “Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase,” J. Medicinal Chem. 38(19):3829-3837 (1995). |
| Fujii et al., “Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid,” Int'l J. Pharmaceutics 222(1):57-64 (2001). |
| Fujii et al., “Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP),” Int'l J. Pharmaceutics 234(1-2):121-128 (2002). |
| Luft et al., “Electro-osmotic valve for the controlled administration of drugs,” Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract). |
| Gan to Kagaku Ryoho, “Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors,” Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract). |
| Gappa et al., “Juvenile laryngeal papillomatosis—a case report,” Pneumologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract). |
| Gause et al., “Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer,” J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996). |
| Ghiglione et al., “How glucagon-like is glucagon-like peptide-1?” Diabetologia 27:599-600 (1984). |
| Glue et al., “A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 571). |
| Goke et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells,” J. Biol. Chem., 268(26):19650-19655 (1993). |
| Gonzales et al., “Randomized controlled trial including an initial 4-week ‘induction’ period during one year of high-dose interferon α-2B treatment for chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975). |
| Gosland et al., “A phase I trial of 5-day continuous infusion cisplatin and interferon alpha,” Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995). |
| Grant et al., “Combination therapy with interferon-α plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study,” J. Med. Virol. 61(4):439-442 (Aug. 2000). |
| Gutniak et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,” N. Engl. J. Med., 326(20):1316-1322 (1992). |
| Hageman, “The Role of Moisture in Protein Stability, ” Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988). |
| Heathcote et al., “Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,” New England J. Med. 343(23):1673-1680 (2000). |
| Reim et al., “Intracellular signaling and antiviral effects of interferons,” Dig. Liver Dis. 32(3):257-263 (Apr. 2000). |
| Heinrich et al., “Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid,” Endocrinol., 115:2176-2181 (1984). |
| Hellstrand et al., “Histamine and cytokine therapy,” Acta Oncol. 37(4):347-353 (1998). |
| Hellstrand et al., “Histamine and the response to IFN-α in chronic hepatitis C,” Interferon Cytokine Res. 18(1):21-22 (Jan. 1998). |
| Hellstrand et al., “Histamine in immunotherapy of advanced melanoma: a pilot study,” Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994). |
| Hisatomi et al., “Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals,” J. Toxicol. Sci., 18(3):1-9 (1993). |
| Hodoshima et al., “Lipid nanoparticles for delivering antitumor drugs,” International Journal of Pharmaceutics, 146(1):81-92 (1997). |
| Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002). |
| Horton et al., “Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice” Cancer Res 59(16):4064-4068 (Aug. 1999). |
| Hubel et al., “A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma” Leukemia 11 Suppl 5:S47-S51 (Dec. 1997). |
| Iacobelli et al., “A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer,” Am. J. Clin. Oncol. 18(1):27-31 (1995). |
| IFNB Multiple Sclerosis Study Group, “Interferonβ-1b is effective in relapsing-remitting multiple sclerosis,” Neurology 43(4):655-667 (Apr. 1993). |
| Interiviune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002). |
| “Introduction to Antibodies”, http://www.chemicon.com/resource/ANT101/a1.asp, 8 pages (retrieved May 2, 2007). |
| Isaacs et al., “Virus interference. I. The interferon,” Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957). |
| Jain et al., “Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system,” J. Microencapsulation 17(3):343-362 (2000). |
| Jordan et al., “Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations,” The Oncologist 12(9):1143-1150 (2007). |
| Kabalnov et al., “Macroemulsion type and stability of alkane-water-phospholipid systems,” Abstracts of Papers, Part 1, 210th ACS National Meeting, 0-8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only). |
| Kabalnov et al., “Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability,” Journal of Colloid and Interface Science 184(1):227-235 (1996). |
| Khalili et al., “Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C,” Am. J. Gastroenterol. 95(5):1284-1289 (May 2000). |
| Kildsig et al., “Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films,” J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970). |
| Kirkwood et al., “Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,” J. Clin. Oncol. 14(1):7-17 (1996). |
| Kita et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ,” Drug Des. Deliv. 6(3):157-0167 (Sep. 1990). |
| Knepp et al, “Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor,” J. Pharm. Sci. Tech. 50(3):163-171 (1996). |
| Knepp et al., “Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures,” Pharma. Res. 15(7):1090-1095 (1998). |
| Knobler et al., “Systemic α-interferon therapy of multiple sclerosis,” Neurology 34(10):1273-1279 (Oct. 1984). |
| Kovacevic et al., “Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon,” Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract). |
| Kracke et al., “Mx proteins in blood leukocytes for monitoring interferon β-1b therapy in patients with MS,” Neurology 54(1):193-199 (Jan. 2000). |
| Kronenberger et al., “Influence of interferon-α on CD82-expression in HCV-positive patients,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 976). |
| Krown et al., “Interferons and interferon inducers in cancer treatment,” Semin. Oncol. 13(2):207-217 (1986). |
| Kubes et al., “Cross-species antiviral and antiproliferative activity of human interferon-ω,” J. Interferon Res. 14:57-59 (1994). |
| Kunzi et al., “Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication,” J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996). |
| Larsson, “Stability of emulsions formed by polar lipids,” Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978). |
| Lee et al., “Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974). |
| Lee, “Therapy of hepatitis C: interferon alfa-2A trials,” Hepatology 26: 89S-95S (Sep. 1997) (XP000981288). |
| Lopez et al., “Mammalian pancreatic preproglucagon contains three glucagon-related peptides,” Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983). |
| Lukaszewski et al., “Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection,” J. Virol. 74(11):5006-5015 (Jun. 2000). |
| Lund et al., “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem,” Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982). |
| Lundberg, “A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol),” J. Pharm. & Pharmacol. 49(1):16-21 (1997). |
| Magnuson et al. “Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells,” Protein Expression & Purification 7:220-228 (1996). |
| Malley et al., “Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration,” Drug Chem Toxicol. 24(4):315-38 (Nov. 2001). |
| Manning et al, “Stability of protein pharmaceuticals,” Pharm. Res. 6(11):903-918 (1989). |
| Marincola et al., “Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer,” J. Clinical Oncol. 13(5):1110-1122 (1995) (X0009078965). |
| Massey, “Interaction of vitamin E with saturated phospholipid bilayers,” Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982). |
| McHutchison et al., “Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998). |
| McHutchison et al., “Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment,” Hepatology 34(4):A333 (Oct. 1, 2001) (XP004716177) (Abstract Only). |
| Meter et al., “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans,” Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006). |
| Merad et al., “Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12),” J. Immunother. 23(3):369-378 (May-Jun. 2000). |
| Milella et al., “Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C virus infection,” Liver 13(3):146-150 (Jun. 1993). |
| Mohler, “Primer on electrodeposited coatings,” Materials Engineering 5:38-45 (1972). |
| Mojsov, “Structural requirements for biological activity of glucagon-like peptide-I,” Int. J. Peptide Protein Research, 40:333-343 (1992). |
| Morgan, “Structure and Moisture Permeability of Film-Forming Poloyers,” Ind. Eng. Chem. 45(10):2296-2306 (1953). |
| Motzer et al., “Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma,” J. Clinical Oncol. 19(5):1312-1319 (2001). |
| Nauck et al., “Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients,” Diabet. Med., 15(11):937-945(1998). |
| Neumann et al., “Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy,” Science 282:103-107 (Dec. 1998). |
| Nieforth et al., “Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-α-2a and a polyethylene glycol-modified derivative in healthy subjects,” Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996). |
| Norden et al., “Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration,” Eur. J. Pharm. Sci. 13(4):393-401 (2001). |
| Olaso et al., “Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C,” Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract). |
| Ortiz et al., “A differential scanning calorimetry study of the interaction of α-tocopherol with mixtures of phospholipids,” Biochim et Biophys Acta 898(2):214-222 (1987). |
| Panitch, “Interferons in multiple sclerosis,” Drugs 44(6):946-962 (Dec. 1992). |
| Patzelt et al., “Identification and processing of proglucagon in pancreatic islets,” Nature, 282:260-266 (1979). |
| Peterson et al., “Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus,” ILAR Journal, 32(3):16-19 (1990). |
| Peterson et al., “Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa),” Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990). |
| Pimstone et al., “High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 973). |
| Plauth et al, “Open-label phase II study of omega interferon in previously untreated HCV infected patients,” Hepatology 34(4):A331 (Oct. 1, 2001) (X004716169) (Abstract Only). |
| Plauth et al, “Open-label study of omega interferon in previously untreated HCV-infected patients,” J. Hepatology 36(Supp. 1):125 (Apr. 2002) (X0002511882) (Abstract Only). |
| Pohl et al., “Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues,” J. Biol. Chem., 273(16):9778-9784 (1998). |
| Poynard et al., “Is an ‘a la carte’ combined interferon α 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C,” Hepatology 31(1):211-218 (Jan. 2000). |
| Poynard et al., “Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus,” Lancet 352(9138):1426-1432 (Oct. 1998). |
| “Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD,” Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release). |
| Quesada et al., “Interferons in Hematological Malignancies”, eds. Baron et al., U. Tex. 487-495 (1987). |
| Quintanar-Guerrero et al., “Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides,” Pharm. Res. 14(2):119-127 (1997). |
| Rajkumar et al., “Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma,” Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998). |
| Roche Pharmaceuticals, Roferon®-A (Interferon alfa-2a, recombinant), 22 pages (2003). |
| Roff et al., “Handbook of Common Polymers”, Cleveland Rubber Co. 72 pages (1971). |
| Rogers et al., “Permeability Valves,” Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957). |
| Roman et al., “Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL,” Transplantation 48(4):554-558 (1989). |
| Roth et al., “High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas,” Acta Oncol. 38(5):613-617 (1999). |
| Roth et al., “Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity,” Endocrinol. 148(12):6054-61 (Dec. 2007). |
| Schepp et al., “Exendin-4 and exendin-(9-39)NH12: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,” Eur. J. Pharmacol., 269(2):183-191 (1994). |
| Schering Corp., Intron® A for Injection, 6 pages (2001). |
| Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003). |
| Schmalfub et al., “Modification of drug penetration into human skin using microemulsions,” J. Controlled Release 46(3):279-285 (1997). |
| Sen et al., “The interferon system: a bird's eye view of its biochemistry,” J. Biol. Chem. 267(8):5017-5020 (Mar. 1992). |
| Shiffman et al., “A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567). |
| Shima et al., “Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment,” J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000). |
| Shiratori et al., “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann. Int. Med. 132(7):517-524 (Apr. 2000). |
| Simon et al., “A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β1a,” Neurology 55(2):185-192 (Jul. 2000). |
| Sparks et al., “Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia,” Metabolism, 47(11):1315-1324 (1998). |
| Sulkowski et al., “Pegylated Interferon Alfa-2A (Pegasys™) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study,” Gastroenterology 118(4, Supp. 2) (2000) (Abstract 236). |
| Sulkowski et al., “Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study,” Biodrugs 16(2):105-109 (2002). |
| Talpaz et al., “Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia,” Blood 98(6):1708-1713 (2001). |
| Talsania et al., “Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice,” Endocrinology 146(9):3748-56 ( Sep. 2005). |
| Tanaka et al., “Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients,” Int. J. Cancer 87(5):741-749 (Sep. 2000). |
| Tong et al., “Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison,” Hepatology 26(6):1640-01645 (Dec. 1997). |
| Touza Rey et al., “The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus,” Ann. Med. Int. 17(2):86-87 (Feb. 2000). |
| Trudeau et al., “A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer,” Cancer Chemother. Pharmacol. 35(6):496-500 (1995). |
| Tseng et al., “Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat,” PNAS USA, 90(5):1992-1996 (1993). |
| Tsung et al., “Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules,” J. Pharm. Sci. 86(5):603-7 (May 1997). |
| Unniappan et al., “Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY,” Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006). |
| Vokes et al., “A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest,” Cancer Chemother. Pharmacol. 35(4):304-312 (1995). |
| Vrabec, “Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing,” Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998). |
| Wang et al., “Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine,” Eur. J. Biochem. 267(21):6362-6368 (2000). |
| Wang et al., “Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines,” Archives of Biochem. & Biophys. 377(2):304-314 (2000). |
| Wang et al., “The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine,” Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000). |
| Wang et al, “Parenteral formulations of proteins and peptides: stability and stabilizers,” J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988). |
| Weinstock-Guttman et al., “What is new in the treatment of multiple sclerosis?” Drugs 59(3):401-410 (Mar. 2000). |
| Weissmann et al., “The interferon genes,” Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986). |
| Wright et al., “Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients,” Transplantation 53(1):121-123 (Jan. 1992). |
| Young et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999). |
| Younossi et al., “The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with α interferons, in the treatment of chronic hepatitis C,” Semin. Liver Dis. 19(Supp. 1):95-102 (1999). |
| Yu et al., “Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog,” J. Pharm. Sci. 85(4):396-401 (1996). |
| Zeidner et al., “Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine,” Antivir. Res. 11(3):147-0160 (Apr. 1989). |
| Zein, “Interferons in the management of viral hepatitis,” Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998). |
| Zeuzem et al., “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C,” New Engl. J. Med. 343(23):1666-1672 (2000). |
| Zeuzem et al., “Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon αon viral turnover,” Hepatology 28(1):245-252 (Jul. 1998). |
| Zhang et al., “Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis,” J. Clinical Pediatrics 14(2):83-84 (1996). |
| Zhang et al, “A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor,” Pharm. Res. 12(10):1447-1452 (1995). |
| Zheng et al. “Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis,” Beijing Med. J. 13(2):80-81 (1998). |
| Ziesche et al., “A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis,” New Engl. J. Med. 341(17):1264-1269 (Oct. 1999). |
| Sanofi-Aventis U.S. LLC, Prescribing Information for Adlyxin® (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages. |
| Amylin Pharmaceuticals, Inc., Prescribing Information for Byetta® (Exenatide) Injection, rev. Oct. 2009, 34 pages. |
| Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon® (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages. |
| Novo Nordisk A/S, Prescribing Information for Victoza® (Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages. |
| Glaxosmithkline LLC, Prescribing Information for Tanzeum® (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages. |
| Eli Lilly & Company, Prescribing Information for Trulicity® (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages. |
| Akers, et al., “Formulation Design and Development of Parenteral Suspensions,” Journal of Parenteral Science & Technology, 41(3): 88-96 (1987). |
| Alonso, et al., “Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres,” Pharmaceutical Research, 10(7):945-953 (1993). |
| Beck, et al., “Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive,” Biology of Reproduction, 28(1): 186-195 (1983). |
| Bodmeier and McGinity, “Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method,” International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988). |
| Cha and Pitt, “A one-week subdermal delivery system for I-methadone based on biodegradable microcapsules,” Journal of Controlled Release, 7: 69-78 (1988). |
| Cha and Pitt, “The acceleration of degradation-controlled drug delivery from polyester microspheres,” Journal of Controlled Release, 8: 259-265 (1989). |
| Cohen, et al., “Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres,” Pharmaceutical Research, 8(6): 713-720 (1991). |
| Conti, et al., “Use of polylactic acid for the preparation of microparticulate drug delivery systems,” Journal of Microencapsulation, 9(2): 153-166 (1992). |
| Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953). |
| Jalil and Nixon, “Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties,” Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990). |
| Lee and Timasheff, “The stabilization of proteins by sucrose,” J. Biological Chem., 256(14): 7193-7201 (Jul. 1981). |
| Li, et al., “Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method,” Journal of Controlled Release, 37: 199-214 (1995). |
| Maa and Hsu, “Liquid-liquid emulsification by static mixers for use in microencapsulation,” Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996). |
| Maulding, et al., “Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament,” Journal of Controlled Release, 3: 103-117 (1986). |
| Mehta, et al.,“Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide),” Journal of Controlled Release, 41: 249-257 (1996). |
| Sah, et al., “A novel method of preparing PLGA microcapsules utilizing methylethyl ketone,” Pharmaceutical Research, 13(3): 360-367 (1996). |
| Sato, et al., “Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques,” Pharmaceutical Research, 5(1): 21-30 (1988). |
| Szayna, et al., “Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats,” Endocrinology, 141(6): 1936-1941 (2000). |
| Thomasin, et al., “A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation,” Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996). |
| van Santbrink and Fauser, “Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens,” J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997). |
| Tracy et al., “Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro.” Biomaterials. 20(11:): 1057-1062 (1999). |
| Ertl et al., “Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines,” Vaccine 14(9):879-885.(1996). |
| Thompson et al., “Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone,” Journal of Controlled Release 43(1):9-22 (1997). |
| Glumetza Brochure 2009, 13 Pages. |
| Erowid,“lntroduction to the Federal Controlled Substance Analog Act” 2001, 4 pages. |
| Li et al. (“Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis of Randomized Controlled Trials” in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010. |
| Georgios, et al., “Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers”, Advances in Therapy, Health Communications, Metuchen, NJ, US, vol. 32, No. 7, Jul. 10, 2015, pp. 650-661. |
| Yu et al., “Glucagon-like peptide 1 based therapy for type 2 diabetes”, World Journal of Pediatrics vol. 4, No. 1, Feb. 1, 2008, pp. 8-13. |
| Taylor et al., “Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes”, Horm Metab Res 37: 627-632 (2005). |
| Gao et al., “Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys. and Humans,” Drug Metabolism and Disposition, vol. 40, No. 5, pp. 990-997 (2012). |
| Number | Date | Country | |
|---|---|---|---|
| 20170252409 A1 | Sep 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61443628 | Feb 2011 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14525201 | Oct 2014 | US |
| Child | 15597788 | US | |
| Parent | 13372326 | Feb 2012 | US |
| Child | 14525201 | US |
